Bombardier reports its third quarter 2021 results, demonstrates solid execution and strong cash flow performance

  • Business aircraft revenues of $1.4 billion, up 17% year–over–year, mainly driven by an improved delivery mix and continued strong aftermarket recovery as overall fleet flight hours surpass 2019 levels.

  • Adjusted EBITDA(1) of $142 million (9.8% adjusted EBITDA margin(1)), representing a year–over–year improvement of $58 million or 69% reflecting continued progress on the Global 7500 aircraft's learning curve, cost structure improvements and an improved delivery mix. Reported EBIT from continuing operations for the quarter was $48 million.

  • Strong free cash flow(1) generation of $100 million from continuing operations, representing an improvement of $747 million year–over–year. Reported cash flows from operating activities "" continuing operations for the quarter was $156 million and net additions to PP&E and intangible assets "" continuing operations for the quarter were $56 million.

  • Third quarter unit book–to–bill(2) of ~1.7 and increased backlog by ~$500 million to $11.2 billion on account of continued strong order momentum.

  • Major milestone in deleveraging plan achieved with the redemption of debt maturities to December 2024, representing a total debt reduction of ~$3 billion since the beginning of 2021.
    Pro–forma liquidity(3) remains strong at $1.9 billion.

All amounts in this press release are in U.S. dollars unless otherwise indicated.
Amounts in tables are in millions, unless otherwise indicated.

MONTREAL, Oct. 28, 2021 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) announced today its financial results for the third quarter of 2021. The company is pleased with continued execution on its strategic initiatives, cash flow generation and order momentum driving the financial results of the quarter. Bombardier also highlighted that during the third quarter, the company redeemed debt maturities through December 2024, a major milestone in its deleveraging plan.

"The Bombardier team once again delivered a solid quarter, a confirmation that this year is shaping up to be significantly better than the last," said ric Martel, President and Chief Executive Officer, Bombardier. "Our unit book–to–bill ratio remains very healthy, contributing to a significant increase to our backlog. This momentum has also translated to a solid increase in profitability, with adjusted EBITDA margin approaching 10% this quarter."

"We are delivering consistently on what we set out to do, especially when it comes to deleveraging the balance sheet. Thanks to the hard work of our outstanding team, we cleared the debt maturity runway on plan," added Martel. "As a fantastic finale to the quarter and at a great moment in time for our industry, we launched our new Challenger 3500 jet last month. The extremely positive reception and strong first orders for the new aircraft are clear evidence that we were able to bring significant value to customers through measured and disciplined investments."

Third Quarter 2021 Financial Performance

Business jet revenues of $1.4 billion are up 17% year–over–year, propelled mainly by an improved delivery mix, with higher deliveries of large aircraft. The company has also seen an increase of revenues by $76 million from business aircraft services. This is mainly due to increased fleet flight hours having now surpassed 2019 levels, a clear signal that the industry is on a strong recovery path from the global shock caused by the COVID–19 pandemic. Confidence levels within the industry are at a new all–time high, indicative of the rising vaccination levels and eased travel restrictions. In the U.S., business jet utilization increased by 42.5%, year–over–year for the first eight months of the year. In Europe, business jet utilization increased by 27.1% year–over–year in the first nine months of the year.

Bombardier reported an adjusted EBITDA of $142 million, representing a year–over–year improvement of $58 million or 69%. The company attributes this to an improved aircraft mix, continued progress on Global 7500 aircraft learning curve, and cost structure improvements. Reported EBIT from continuing operations for the quarter was $48 million.

For the second consecutive quarter, the company is seeing an improved free cash flow (FCF) generation. FCF of $100 million from continuing operations represents an improvement of $747 million year–over–year. The positive result is mainly due to stronger order intake and better payment terms on new orders. Reported cash flows from operating activities "" continuing operations for the quarter was $156 million, and net additions to PP&E and intangible assets "" continuing operations for the quarter were $56 million.

Major Milestone Achieved with the Clearing of Debt Maturities Through December 2024

The Corporation reported a total debt reduction of approximately $3 billion since the beginning of 2021, and cleared, through redemption or refinancing, debt maturities through December 2024. This represents a major milestone in one of Bombardier's key priorities this year, as it creates a runway to focus on its operations and stabilizes the need for liquidity. Pro–forma liquidity remains strong at $1.9 billion.

Successful launch of the Challenger 3500

As the third quarter wrapped up, the company introduced a major update to its bestselling Challenger 350 platform, the Challenger 3500. The new aircraft represents a culmination of a period of important product development that saw Bombardier introduce innovative technologies and industry–leading new products and services.

With a redesigned interior that includes Bombardier's patented Nuage seat as part of the aircraft's standard configuration and the industry's first voice–controlled cabin, the new Challenger 3500 further elevates the cabin experience to meet the increasing customer expectations. The enthusiastic welcome that the mock–up of the aircraft received at the first post–pandemic National Business Aviation Association event earlier this month is a first confirmation of this, as is a 20 aircraft firm order announced in the third quarter.

Flight testing and certification activities for the Challenger 3500 is progressing on schedule for an expected entry into service in the second half of 2022.

SELECTED RESULTS
Results of the Quarter
Three–month periods ended September 30 2021 2020 Variance
restated(4)
Revenues(5) $ 1,449 $ 1,405 3 %
Adjusted EBITDA(5) $ 142 $ 84 69 %
Adjusted EBITDA margin(5) 9.8 % 6.0 % 380 bps
Adjusted EBIT(1)(5) $ 49 $ (11 ) nmf
Adjusted EBIT margin(1) (5) 3.4 % (0.8 ) % 420 bps
EBIT(5) $ 48 $ (29 ) nmf
EBIT margin(5) 3.3 % (2.1 ) % 540 bps
Net loss from continuing operations $ (376 ) $ (24 ) (1,467 ) %
Net income (loss) from discontinued operations $ (1 ) $ 216 nmf
Net income (loss) $ (377 ) $ 192 nmf
Diluted EPS from continuing operations (in dollars) $ (0.16 ) $ (0.01 ) $ (0.15 )
Diluted EPS from discontinued operations (in dollars) $ "" $ 0.06 $ (0.06 )
$ (0.16 ) $ 0.05 $ (0.21 )
Adjusted net loss(1) (5) $ (95 ) $ (210 ) 55 %
Adjusted EPS (in dollars) (1) (5) $ (0.04 ) $ (0.09 ) $ 0.05
Cash flows from operating activities
Continuing operations $ 156 $ (611 ) nmf
Discontinued operations $ "" $ (33 ) 100 %
$ 156 $ (644 ) nmf
Net additions to PP&E and intangible assets
Continuing operations $ 56 $ 36 56 %
Discontinued operations $ "" $ 26 (100 ) %
$ 56 $ 62 (10 ) %
Free cash flow (usage)
Continuing operations $ 100 $ (647 ) nmf
Discontinued operations $ "" $ (59 ) 100 %
$ 100 $ (706 ) nmf
As at September 30, 2021
December 31, 2020 Variance
Cash and cash equivalents excluding Transportation $ 1,380 $ 1,779 (22 ) %
Cash and cash equivalents from Transportation $ "" $ 671 (100 ) %
$ 1,380 $ 2,450 (44 ) %
Available short–term capital resources(6) $ 1,380 $ 3,203 (57 ) %
Aviation order backlog (in billions of dollars)
Business aircraft(7) $ 11.2 $ 10.7 5 %

About Bombardier

Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of over 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Visit the Bombardier Business Aircraft website for more information on our industry–leading products and services.

Bombardier, Global, Global 7500, Challenger, Challenger 350 and Challenger 3500 are trademarks of Bombardier Inc. or its subsidiaries.

For Information

Francis Richer de La Flche Anna Cristofaro
Vice President, Financial Planning and Investor Relations Manager, Communications
Bombardier Bombardier
+1 514 855 5001 x13228 +1 514 855 8678

The Management's Discussion and Analysis and the Interim Consolidated Financial Statements are available at ir.bombardier.com.

bps: basis points
nmf: information not meaningful
(1) Non–GAAP financial measures. Refer to the Non–GAAP financial measures section in Overview for definitions of these metrics and to the Analysis of consolidated results section and Liquidity and capital resources section in Overview for reconciliations to the most comparable IFRS measures.
(2) Defined as net new aircraft orders in units over aircraft deliveries in units.
(3) Non–GAAP measures. Pro–forma liquidity is defined as cash and cash equivalents as at September 30, 2021 of $1.4 billion plus $0.5 billion of short–term restricted cash as collateral for bank guarantees.
(4) Restated for the sale of Transportation, refer to Note 17 "" Disposal of business to our Interim consolidated financial statements for more details.
(5) Includes continuing operations only.
(6) Defined as cash and cash equivalents as at September 30, 2021; defined as cash and cash equivalents including cash and cash equivalents from Transportation plus the undrawn amounts under Transportation's revolving credit facility and our senior secured term loan as at
December 31, 2020.
(7) Includes order backlog for both manufacturing and services.

CAUTION REGARDING NON–GAAP FINANCIAL MEASURES

This press release is based on reported earnings in accordance with IFRS and on the following non–GAAP financial measures:

Non–GAAP financial measures
Adjusted EBIT EBIT excluding special items. Special items comprise items which do not reflect the Corporation's core performance or where their separate presentation will assist users of the consolidated financial statements in understanding the Corporation's results for the period. Such items include, among others, the impact of restructuring charges, impact of business disposals and significant impairment charges and reversals.
Adjusted EBITDA Adjusted EBIT plus amortization and impairment charges on PP&E and intangible assets.
Adjusted net income (loss) Net income (loss) excluding special items, accretion on net retirement benefit obligations, certain net gains and losses arising from changes in measurement of provisions and of financial instruments carried at FVTP&L and the related tax impacts of these items.
Adjusted EPS EPS calculated based on adjusted net income attributable to equity holders of Bombardier Inc., using the treasury stock method, giving effect to the exercise of all dilutive elements.
Free cash flow (usage) Cash flows from operating activities less net additions to PP&E and intangible assets.

Non–GAAP financial measures are mainly derived from the consolidated financial statements but do not have standardized meanings prescribed by IFRS. The exclusion of certain items from non–GAAP performance measures does not imply that these items are necessarily non–recurring. Other entities in our industry may define the above measures differently than we do. In those cases, it may be difficult to compare the performance of those entities to ours based on these similarly–named non–GAAP measures.

Adjusted EBIT, adjusted EBITDA, adjusted net income (loss) and adjusted EPS

Management uses adjusted EBIT, adjusted EBITDA, adjusted net income (loss) and adjusted EPS for purposes of evaluating underlying business performance. Management believes these non–GAAP earnings measures in addition to IFRS measures provide users of our Financial Report with enhanced understanding of our results and related trends and increases the transparency and clarity of the core results of our business. Adjusted EBIT, adjusted EBITDA, adjusted net income (loss) and adjusted EPS exclude items that do not reflect our core performance or where their exclusion will assist users in understanding our results for the period. For these reasons, a significant number of users of the MD&A analyze our results based on these financial measures. Management believes these measures help users of MD&A to better analyze results, enabling better comparability of our results from one period to another and with peers.

Free cash flow (usage)

Free cash flow is defined as cash flows from operating activities less net additions to PP&E and intangible assets. Management believes that this non–GAAP cash flow measure provides investors with an important perspective on the Corporation's generation of cash available for shareholders, debt repayment, and acquisitions after making the capital investments required to support ongoing business operations and long–term value creation. This non–GAAP cash flow measure does not represent the residual cash flow available for discretionary expenditures as it excludes certain mandatory expenditures such as repayment of maturing debt. Management uses free cash flow as a measure to assess both business performance and overall liquidity generation.

Reconciliations of non–GAAP financial measures to the most comparable IFRS financial measures are provided in the table hereafter, except for the following reconciliations:

  • adjusted EBIT to EBIT "" see the Consolidated results of operations section; and
  • free cash flow usage to cash flows from operating activities "" see the Free cash flow usage table in the Liquidity and capital resources section.
Reconciliation of adjusted EBITDA to EBIT(1)
Three–month periods
ended September 30
Nine–month periods
ended September 30
2021
2020 2021
2020
EBIT $ 48 $ (29 ) $ 103 $ 479
Amortization 93 95 298 247
Impairment charges on PP&E(2) "" 6 3 25
Special items excluding impairment charges
on PP&E(2)
1 12 4 (550 )
Adjusted EBITDA $ 142 $ 84 $ 408 $ 201

(1) Includes continuing operations only.
(2) Refer to the Consolidated results of operations section for details regarding special items.

FORWARD–LOOKING STATEMENTS

This press release includes forward–looking statements, which may involve, but are not limited to: statements with respect to our objectives, anticipations and outlook or guidance in respect of various financial and global metrics and sources of contribution thereto, targets, goals, priorities, market and strategies, financial position, financial performance, market position, capabilities, competitive strengths, credit ratings, beliefs, prospects, plans, expectations, anticipations, estimates and intentions; general economic and business outlook, prospects and trends of an industry; customer value; expected demand for products and services; growth strategy; product development, including projected design, characteristics, capacity or performance; expected or scheduled entry–into–service of products and services, orders, deliveries, testing, lead times, certifications and execution of orders in general; competitive position; expectations regarding revenue and backlog mix; the expected impact of the legislative and regulatory environment and legal proceedings; strength of capital profile and balance sheet, creditworthiness, available liquidities and capital resources, expected financial requirements, and ongoing review of strategic and financial alternatives; the introduction of, productivity enhancements, operational efficiencies, cost reduction and restructuring initiatives, and anticipated costs, intended benefits and timing thereof; the anticipated business transition to growth cycle and cash generation; expectations, objectives and strategies regarding debt repayment, refinancing of maturities and interest cost reduction; expectations regarding availability of government assistance programs, compliance with restrictive debt covenants; expectations regarding the declaration and payment of dividends on our preferred shares; intentions and objectives for our programs, assets and operations; and the impact of the COVID–19 pandemic on the foregoing and the effectiveness of plans and measures we have implemented in response thereto; and expectations regarding the strength of the market and economic recovery in the aftermath of the COVID–19 pandemic. As it relates to the sale of the Transportation business to Alstom, this press release also contains forward–looking statements with respect to the benefits of such transaction, the use of the proceeds derived from the transaction and its impact on our outlook, guidance and targets, operations, infrastructure, opportunities, financial condition, business plan and overall strategy.

Forward–looking statements can generally be identified by the use of forward–looking terminology such as "may", "will", "shall", "can", "expect", "estimate", "intend", "anticipate", "plan", "foresee", "believe", "continue", "maintain" or "align", the negative of these terms, variations of them or similar terminology. Forward–looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of our current objectives, strategic priorities, expectations, outlook and plans, and in obtaining a better understanding of our business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

By their nature, forward–looking statements require management to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecast results set forth in forward–looking statements. While management considers these assumptions to be reasonable and appropriate based on information currently available, there is risk that they may not be accurate. The assumptions underlying the forward–looking statements made in this press release include the following material assumptions: the deployment of the proceeds from the sale of the Transportation business to Alstom on terms allowing the Corporation, when combined with other financing sources and free cash flow generation, to repay or otherwise manage its financial obligations for the next three years; growth of the business aviation market and increase of the Corporation's share of such market; proper identification of recurring cost savings and executing on our cost reduction plan; optimization of our real estate portfolio, including through the sale or other transaction in respect of real estate assets on favorable terms; and access to working capital facilities on market terms. For additional information, including with respect to other assumptions underlying the forward–looking statements made in this press release, refer to the Forward–looking statements "" Assumptions section in the MD&A of our financial report for the fiscal year ended December 31, 2020. Given the impact of the changing circumstances surrounding the COVID–19 pandemic and the related response from the Corporation, governments (federal, provincial and municipal), regulatory authorities, businesses, suppliers, customers, counterparties and third–party service providers, there is inherently more uncertainty associated with the Corporation's assumptions as compared to prior years.

Certain factors that could cause actual results to differ materially from those anticipated in the forward–looking statements include, but are not limited to, risks associated with general economic conditions, risks associated with our business environment (such as risks associated with the financial condition of business aircraft customers; trade policy; increased competition; political instability and force majeure events or global climate change), operational risks (such as risks related to developing new products and services; development of new business ; order backlog; the transition to a pure–play business aviation company; the certification of products and services; the execution of orders; pressures on cash flows and capital expenditures based on seasonality and cyclicality; execution of our strategy, productivity enhancements, operational efficiencies, restructuring and cost reduction initiatives; doing business with partners; product performance warranty and casualty claim losses; regulatory and legal proceedings; environmental, health and safety risks; dependence on certain customers, contracts and suppliers; supply chain risks; human resources; reliance on information systems; reliance on and protection of intellectual property rights; reputation risks; risk management; tax matters; and adequacy of insurance coverage), financing risks (such as risks related to liquidity and access to capital markets; retirement benefit plan risk; exposure to credit risk; substantial debt and interest payment requirements; restrictive debt covenants; reliance on debt management and interest cost reduction strategies; and reliance on government support), market risks (such as foreign currency fluctuations; changing interest rates; increases in commodity prices; and inflation rate fluctuations). For more details, see the Risks and uncertainties section in Other in the MD&A of our financial report for the fiscal year ended December 31, 2020. Any one or more of the foregoing factors may be exacerbated by the ongoing COVID–19 outbreak and may have a significantly more severe impact on the Corporation's business, results of operations and financial condition than in the absence of such outbreak. As a result of the current COVID–19 pandemic, additional factors that could cause actual results to differ materially from those anticipated in the forward–looking statements include, but are not limited to: risks related to the impact and effects of the COVID–19 pandemic on economic conditions and financial markets and the resulting impact on our business, operations, capital resources, liquidity, financial condition, margins, prospects and results; uncertainty regarding the magnitude and length of economic disruption as a result of the COVID–19 outbreak and the resulting effects on the demand environment for our products and services; uncertainty regarding market and economic recovery in the aftermath of the COVID–19 pandemic; emergency measures and restrictions imposed by public health authorities or governments, fiscal and monetary policy responses by governments and financial institutions; disruptions to global supply chain, customers, workforce, counterparties and third–party service providers; further disruptions to operations, orders and deliveries; technology, privacy, cyber security and reputational risks; and other unforeseen adverse events.

Readers are cautioned that the foregoing list of factors that may affect future growth, results and performance is not exhaustive and undue reliance should not be placed on forward–looking statements. Other risks and uncertainties not presently known to us or that we presently believe are not material could also cause actual results or events to differ materially from those expressed or implied in our forward–looking statements. The forward–looking statements set forth herein reflect management's expectations as at the date of this report and are subject to change after such date. Unless otherwise required by applicable securities laws, we expressly disclaim any intention, and assume no obligation to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise. The forward–looking statements contained in this press release are expressly qualified by this cautionary statement.


GLOBENEWSWIRE (Distribution ID 8381754)

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID–19 to be Presented at IDWeek 2021

Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment

$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody–based Solutions for Infectious Diseases with Pandemic Potential

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID–19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

"Across the globe, COVID–19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks," said Tillman Gerngross, Ph.D., co–founder and chief executive officer of Adagio. "Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.

"ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID–19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women," said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. "To date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS–CoV–2 virus and the known variants of concerns in in vitro models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year's IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic."

ADG20 COVID–19 Program Highlights

  • New ADG20 Data to be Presented in Multiple Posters during IDWeek: At the IDWeek 2021 Virtual Conference, Adagio plans to present additional data highlighting the potential for ADG20 to provide protection from COVID–19 for up to one year based on its extended half–life in humans combined with its broad and potent neutralizing ability demonstrated in laboratory testing. In addition, the data support the evaluation of a 300mg dose, delivered as a single intramuscular injection, in the ongoing Phase 2/3 STAMP (treatment) and EVADE (prevention) global clinical trials. The data will be presented in multiple posters, which will be available to registered attendees on the virtual platform throughout the duration of the conference, being held from September 29 "" October 3, 2021. The presentations include:
    • 1086: A Whole–Body Quantitative System Pharmacology Physicologically–Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half–life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID–19)
    • 633: Preliminary Results from a Phase 1 Single Ascending–Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half–Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID–19)
    • 1089: Use of a Whole–Body Quantitative System Pharmacology Physiologically–Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half–Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID–19)
    • 1088: A Whole–Body Quantitative System Pharmacology Physiologically–Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half–Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID–19)
  • Patient Population Expanded in EVADE following IDMC Data Assessment: The independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID–19 recently provided a recommendation to expand Phase 3 trial enrollment to include adolescents 12 years and older and pregnant or nursing women, as well as a decrease in the protocol–specified, in–clinic post injection monitoring time. The IDMC's recommendations were based on their review of unblinded safety and tolerability data through the Day 28 post–treatment visit from 200 participants enrolled in the Phase 2 lead–in portion of the trial.
  • Partnership with Biocon Biologics Expands the Reach of a Potent and Broadly Neutralizing COVID–19 Antibody Treatment to Patients in India and Select Emerging Markets: In the second quarter of 2021, Adagio partnered with Biocon Biologics Ltd. to combat the ongoing COVID–19 crisis in southern Asia. The partnership provides Biocon rights to manufacture and commercialize an antibody therapy based on ADG20 in India and additional select emerging markets based on the commercial manufacturing process developed for ADG20. As part of the agreement, Biocon will be granted access to data from Adagio's Phase 2/3 clinical trials as well as its anticipated Emergency Use Authorization package and other regulatory submissions to support approval or emergency authorization in India and other select emerging markets.

Recent Business Highlights

  • David Hering, Global COVID–19 Vaccine Expert, Appointed as Chief Operating Officer: Adagio recently appointed David Hering as the company's chief operating officer. Mr. Hering joins Adagio from Pfizer, where he most recently served as the global mRNA business lead, a business specifically created to manage global COVID–19 efforts as well as future vaccines utilizing mRNA technology, and led the launch of the first–ever COVID–19 vaccine in the United States. Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700–person organization across a portfolio of vaccine products for COVID–19 and meningococcal and pneumococcal diseases.
  • $355.8 Million Initial Public Offering (IPO) Successfully Completed: In August 2021, Adagio sold 20,930,000 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 2,730,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds of the offering, before underwriting discounts and commissions and other offering expenses payable by Adagio, were approximately $355.8 million.
  • Collaboration with Scripps: Adagio entered into an exclusive research agreement with The Scripps Research Institute to identify broadly protective vaccine candidates for the prevention of influenza and beta coronaviruses.
  • Board of Directors Expanded with Industry Leaders to Support Future Growth: Adagio recently announced appointments of three industry veterans and area experts to its board of directors:
    • Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC);
    • Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA); and
    • Michael S. Wyzga, president of MSW Consulting, Inc. and former CFO of Genzyme

Second Quarter 2021 Financial Results

  • As of June 30, 2021, Adagio had cash, cash equivalents and marketable securities of $392.5 million, which includes net proceeds from its Series C financing completed in April. Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our initial public offering which closed on August 10, 2021.
  • Research & development expenses including in–process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.
  • Net Loss for the second quarter was $44.7 million, or $0.18 per share.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS–CoV–2 and related coronaviruses, is being developed for the prevention and treatment of COVID–19, the disease caused by SARS–CoV–2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS–CoV–2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS–CoV–2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc–mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half–life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential. The company's portfolio of antibodies has been optimized using Adimab's industry–leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half–life extension), manufacturability and affordability. Adagio's portfolio of SARS–CoV–2 antibodies includes multiple, non–competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third–party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward–looking statements. Forward–looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward–looking statements and you should not place undue reliance on our forward–looking statements. These forward–looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward–looking statements, including, without limitation, those risks described under the heading "Risk Factors" in Adagio's prospectus filed with the Securities and Exchange Commission ("SEC") on August 6, 2021 and in Adagio's future reports to be filed with the SEC, including Adagio's Quarterly Report on Form 10–Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID–19 pandemic. Forward–looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share amounts)

June 30,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents(1) $ 392,509 $ 114,988
Prepaid expenses and other current assets 3,550 2,394
Total current assets 396,059 117,382
Deferred offering costs 1,933 ""
Total assets $ 397,992 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders' Deficit
Current liabilities:
Accounts payable $ 10,716 $ 8,153
Accrued expenses 27,181 4,919
Total current liabilities 37,897 13,072
Early–exercise liability 8 11
Total liabilities 37,905 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; 16,944,484 shares authorized, issued and outstanding at June 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $505,399 and $169,900 at June 30, 2021 and December 31, 2020, respectively 504,711 169,548
Stockholders' deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020; 5,599,240 shares issued and outstanding at June 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 1 1
Treasury stock, at cost; 0 shares and 22,600,000 shares at June 30, 2021 and December 31, 2020, respectively "" (85 )
Additional paid–in capital 4,067 154
Accumulated deficit (148,692 ) (65,319 )
Total stockholders' deficit (144,624 ) (65,249 )
Total liabilities, convertible preferred stock and stockholders' deficit $ 397,992 $ 117,382

(1) Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our issuance and sale of 20,930,000 shares of our common stock in our initial public offering at the price of $17.00 per share after deducting underwriting discounts, commissions and estimated offering costs which closed on August 10, 2021.

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands, except share and per share amounts)

Three Months
Ended
June 30,
Six Months
Ended
June 30,
Period from
June 3, 2020
(Inception) to
June 30,
2021 2021 2020 (3)
Operating expenses:
Research and development(1) $ 35,067 $ 69,204 $ 48
Acquired in–process research and development(2) 2,500 3,500 ""
Selling, general and administrative 7,124 10,695 50
Total operating expenses 44,691 83,399 98
Loss from operations (44,691 ) (83,399 ) (98 )
Other income (expense):
Interest income 23 32 ""
Other expense (5 ) (6 ) ""
Total other income (expense), net 18 26 ""
Net loss and comprehensive loss $ (44,673 ) $ (83,373 ) $ (98 )
Net loss per share attributable to common stockholders, basic and
diluted
$ (0.18 ) $ (0.66 ) $ ""
Weighted–average common shares outstanding, basic and diluted 249,769 125,574 21,250,000

(1) Includes related–party amounts of $247 for the three months ended June 30, 2021, $435 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(2) Includes related–party amounts of $2,500 for the three months ended June 30, 2021, $3,500 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(3) The results for the period from June 3, 2020 (inception) to June 30, 2020 are the same for the three and six months ended June 30, 2020.


GLOBENEWSWIRE (Distribution ID 8328556)

CORRECTION – Zoom Reports Financial Results for the Second Quarter of Fiscal Year 2022

  • Second quarter total revenue of $1,021.5 million, up 54% year over year
  • Number of customers contributing more than $100,000 in TTM revenue up 131% year over year
  • Second quarter GAAP operating margin of 28.8% and non–GAAP operating margin of 41.6%

SAN JOSE, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) is updating this press release to include the "Amortization on marketable securities" line item in its condensed consolidated statements of cash flows. Complete corrected text follows.

Zoom Video Communications, Inc. (NASDAQ: ZM) today announced financial results for the second fiscal quarter ended July 31, 2021.

"In Q2, we achieved our first billion dollar revenue quarter while delivering strong profitability and cash flow," said Zoom founder and CEO, Eric S. Yuan. "Q2 also marked several milestones on our expansion beyond the UC platform. We launched Zoom Apps, bringing over 50 apps directly into the Zoom experience, and Zoom Events, an all–in–one digital events service. Today we are a global brand counting over half a million customers with more than 10 employees, which we believe positions us extremely well to support organizations and individuals as they look to reimagine work, communications, and collaboration."

Second Quarter Fiscal Year 2022 Financial Highlights:

  • Revenue: Total revenue for the second quarter was $1,021.5 million, up 54% year over year.
  • Income from Operations and Operating Margin: GAAP income from operations for the second quarter was $294.6 million, up from $188.1 million in the second quarter of fiscal year 2021. After adjusting for stock–based compensation expense and related payroll taxes, acquisition–related expenses, and expenses related to charitable donation of common stock, non–GAAP income from operations for the second quarter was $424.7 million, up from $277.0 million in the second quarter of fiscal year 2021. For the second quarter, GAAP operating margin was 28.8% and non–GAAP operating margin was 41.6%.
  • Net Income and Diluted Net Income Per Share: GAAP net income attributable to common stockholders for the second quarter was $316.9 million, or $1.04 per share, up from $185.7 million, or $0.63 per share in the second quarter of fiscal year 2021.

    Non–GAAP net income for the quarter was $415.1 million, after adjusting for stock–based compensation expense and related payroll taxes, acquisition–related expenses, gains on strategic investments, undistributed earnings attributable to participating securities, and expenses related to charitable donation of common stock. Non–GAAP net income per share was $1.36. In the second quarter of fiscal year 2021, non–GAAP net income was $274.8 million, or $0.92 per share.

  • Cash and Marketable Securities: Total cash, cash equivalents, and marketable securities, excluding restricted cash, as of July 31, 2021 was $5.1 billion.
  • Cash Flow: Net cash provided by operating activities was $468.0 million for the second quarter, compared to $401.3 million in the second quarter of fiscal year 2021. Free cash flow, which is net cash provided by operating activities less purchases of property and equipment, was $455.0 million, compared to $373.4 million in the second quarter of fiscal year 2021.

Customer Metrics: Drivers of total revenue included acquiring new customers and expanding across existing customers. At the end of the second quarter of fiscal year 2022, Zoom had:

  • 2,278 customers contributing more than $100,000 in trailing 12 months revenue, up approximately 131% from the same quarter last fiscal year.
  • Approximately 504,900 customers with more than 10 employees, up approximately 36% from the same quarter last fiscal year.
  • A trailing 12–month net dollar expansion rate in customers with more than 10 employees above 130% for the 13th consecutive quarter.

Financial Outlook: Zoom is providing the following guidance for its third quarter fiscal year 2022 and its full fiscal year 2022.

  • Third Quarter Fiscal Year 2022: Total revenue is expected to be between $1.015 billion and $1.020 billion and non–GAAP income from operations is expected to be between $340.0 million and $345.0 million. Non–GAAP diluted EPS is expected to be between $1.07 and $1.08 with approximately 309 million non–GAAP weighted average shares outstanding.
  • Full Fiscal Year 2022: Total revenue is expected to be between $4.005 billion and $4.015 billion. Non–GAAP income from operations is expected to be between $1.500 billion and $1.510 billion. Non–GAAP diluted EPS is expected to be between $4.75 and $4.79 with approximately 308 million non–GAAP weighted average shares outstanding.

Additional information on Zoom's reported results, including a reconciliation of the non–GAAP results to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non–GAAP guidance measures to corresponding GAAP measures is not available on a forward–looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Zoom's results computed in accordance with GAAP.

A supplemental financial presentation and other information can be accessed through Zoom's investor relations website at investors.zoom.us.

Zoom Video Earnings Call
Zoom will host a Zoom Video Webinar for investors on August 30, 2021 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the company's financial results and business highlights. Investors are invited to join the Zoom Video Webinar by visiting: https://investors.zoom.us/

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Forward–Looking Statements
This press release contains express and implied "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook for the third quarter of fiscal year 2022 and full fiscal year 2022, Zoom's growth strategy and business aspirations to support organizations and people on multiple fronts as they look to reimagine work, communications and collaboration. In some cases, you can identify forward–looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward–looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including: declines in new customers and hosts, renewals or upgrades, difficulties in evaluating our prospects and future results of operations given our limited operating history, competition from other providers of communications platforms, continued uncertainty regarding the extent and duration of the impact of COVID–19 and the responses of government and private industry thereto, including the potential effect on our user growth rate once the impact of the COVID–19 pandemic tapers, particularly as a vaccine becomes widely available, and users return to work or school or are otherwise no longer subject to shelter–in–place mandates, as well as the impact of COVID–19 on the overall economic environment, any or all of which will have an impact on demand for remote work solutions for businesses as well as overall distributed, face–to–face interactions and collaboration using Zoom, delays or outages in services from our co–located data centers, and failures in internet infrastructure or interference with broadband access which could cause current or potential users to believe that our systems are unreliable. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward–looking statements are included under the caption "Risk Factors" and elsewhere in our most recent filings with the Securities and Exchange Commission (the "SEC"), including our quarterly report on Form 10–Q for the fiscal quarter ended April 30, 2021. Forward–looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward–looking statements to reflect events or circumstances after the date they were made, except as required by law.

Non–GAAP Financial Measures
Zoom has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Zoom uses these non–GAAP financial measures internally in analyzing its financial results and believes that use of these non–GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing Zoom's financial results with other companies in its industry, many of which present similar non–GAAP financial measures.

Non–GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with Zoom's condensed consolidated financial statements prepared in accordance with GAAP. A reconciliation of Zoom's historical non–GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.

Non–GAAP Income From Operations and Non–GAAP Operating Margins. Zoom defines non–GAAP income from operations as income from operations excluding stock–based compensation expense and related payroll taxes, expenses related to charitable donation of common stock, acquisition–related expenses, and litigation settlements, net. Zoom excludes stock–based compensation expense and expenses related to charitable donation of common stock because they are non–cash in nature and excluding these expenses provides meaningful supplemental information regarding Zoom's operational performance and allows investors the ability to make more meaningful comparisons between Zoom's operating results and those of other companies. Zoom excludes the amount of employer payroll taxes related to employee stock plans, which is a cash expense, in order for investors to see the full effect that excluding stock–based compensation expense had on Zoom's operating results. In particular, this expense is dependent on the price of our common stock and other factors that are beyond our control and do not correlate to the operation of the business. Zoom views acquisition–related expenses when applicable, such as amortization of acquired intangible assets, transaction costs, and acquisition–related retention payments that are directly related to business combinations as events that are not necessarily reflective of operational performance during a period. Zoom excludes significant litigation settlements, net of amounts covered by insurance, that we deem not to be in the ordinary course of our business. In particular, Zoom believes the consideration of measures that exclude such expenses can assist in the comparison of operational performance in different periods which may or may not include such expenses and assist in the comparison with the results of other companies in the industry.

Non–GAAP Net Income and Non–GAAP Net Income Per Share, Basic and Diluted. Zoom defines non–GAAP net income and non–GAAP net income per share, basic and diluted, as GAAP net income attributable to common stockholders and GAAP net income per share attributable to common stockholders, basic and diluted, respectively, adjusted to exclude stock–based compensation expense and related payroll taxes, expenses related to charitable donation of common stock, acquisition–related expenses, litigation settlements, net, gains on strategic investments, and undistributed earnings attributable to participating securities. Zoom excludes gains on strategic investments because given the size and volatility in the ongoing adjustments to the valuation of our strategic investments, we believe that excluding these gains or losses facilitates a more meaningful evaluation of our operational performance. Zoom excludes undistributed earnings attributable to participating securities because they are considered by management to be outside of Zoom's core operating results, and excluding them provides investors and management with greater visibility to the underlying performance of Zoom's business operations, facilitates comparison of its results with other periods and may also facilitate comparison with the results of other companies in the industry.

In order to calculate non–GAAP net income per share, basic and diluted, Zoom uses a non–GAAP weighted–average share count. Zoom defines non–GAAP weighted–average shares used to compute non–GAAP net income per share, basic and diluted, as GAAP weighted average shares used to compute net income per share attributable to common stockholders, basic and diluted, adjusted to reflect the common stock issued in connection with the IPO, including the concurrent private placement, that are outstanding as of the end of the period as if they were outstanding as of the beginning of the period for comparability.

Free Cash Flow. Zoom defines free cash flow as GAAP net cash provided by operating activities less purchases of property and equipment. Zoom considers free cash flow to be a liquidity measure that provides useful information to management and investors regarding net cash provided by operating activities and cash used for investments in property and equipment required to maintain and grow the business.

Customer Metrics
Zoom defines a customer as a separate and distinct buying entity, which can be a single paid host or an organization of any size (including a distinct unit of an organization) that has multiple paid hosts.

Zoom calculates net dollar expansion rate as of a period end by starting with the annual recurring revenue ("ARR") from all customers with more than 10 employees as of 12 months prior ("Prior Period ARR"). Zoom defines ARR as the annualized revenue run rate of subscription agreements from all customers at a point in time. We then calculate the ARR from these customers as of the current period end ("Current Period ARR"), which includes any upsells, contraction, and attrition. Zoom divides the Current Period ARR by the Prior Period ARR to arrive at the net dollar expansion rate. For the trailing 12 months calculation, Zoom takes an average of the net dollar expansion rate over the trailing 12 months.

Press Relations

Colleen Rodriguez
Global Public Relations Lead for Zoom
press@zoom.us

Investor Relations

Tom McCallum
Head of Investor Relations for Zoom
investors@zoom.us



Zoom Video Communications, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)

As of
July 31,
2021
January 31,
2021
Assets
Current assets:
Cash and cash equivalents $ 1,931,370 $ 2,240,303
Marketable securities 3,174,029 2,004,410
Accounts receivable, net 395,266 294,703
Deferred contract acquisition costs, current 162,126 136,630
Prepaid expenses and other current assets 172,288 116,819
Total current assets 5,835,079 4,792,865
Deferred contract acquisition costs, noncurrent 154,971 157,262
Property and equipment, net 193,852 149,924
Operating lease right–of–use assets 91,087 97,649
Strategic investments 137,795 18,668
Goodwill 26,247 24,340
Other assets, noncurrent 69,562 57,285
Total assets $ 6,508,593 $ 5,297,993
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 49,762 $ 8,664
Accrued expenses and other current liabilities 482,162 393,018
Deferred revenue, current 1,154,449 858,284
Total current liabilities 1,686,373 1,259,966
Deferred revenue, noncurrent 23,579 25,211
Operating lease liabilities, noncurrent 83,009 90,415
Other liabilities, noncurrent 57,884 61,634
Total liabilities 1,850,845 1,437,226
Stockholders' equity:
Preferred stock "" ""
Common stock 296 292
Additional paid–in capital 3,440,222 3,187,168
Accumulated other comprehensive income 147 839
Retained earnings 1,217,083 672,468
Total stockholders' equity 4,657,748 3,860,767
Total liabilities and stockholders' equity $ 6,508,593 $ 5,297,993

Note: The amount of unbilled accounts receivable included within accounts receivable, net on the condensed consolidated balance sheets was $35.4 million and $24.6 million as of July 31, 2021 and January 31, 2021, respectively.



Zoom Video Communications, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share amounts)

Three Months Ended July 31, Six Months Ended July 31,
2021 2020 2021 2020
Revenue $ 1,021,495 $ 663,520 $ 1,977,732 $ 991,687
Cost of revenue 261,256 192,271 526,250 295,978
Gross profit 760,239 471,249 1,451,482 695,709
Operating expenses:
Research and development 82,311 42,734 147,486 69,123
Sales and marketing 271,179 159,173 516,846 280,729
General and administrative 112,146 81,238 266,235 134,368
Total operating expenses 465,636 283,145 930,567 484,220
Income from operations 294,603 188,104 520,915 211,489
Gains on strategic investments 32,076 "" 32,076 2,538
Interest income and other, net (2,795 ) 2,081 (176 ) 5,333
Income before provision for income taxes 323,884 190,185 552,815 219,360
Provision for income taxes 6,800 4,196 8,200 6,296
Net income 317,084 185,989 544,615 213,064
Undistributed earnings attributable to participating securities (154 ) (247 ) (309 ) (305 )
Net income attributable to common stockholders $ 316,930 $ 185,742 $ 544,306 $ 212,759
Net income per share attributable to common stockholders:
Basic $ 1.07 $ 0.66 $ 1.85 $ 0.76
Diluted $ 1.04 $ 0.63 $ 1.78 $ 0.72
Weighted–average shares used in computing net income per share attributable to common stockholders:
Basic 295,712,675 282,850,805 294,769,619 281,394,901
Diluted 305,861,051 297,162,309 305,652,628 296,408,229



Zoom Video Communications, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

Three Months Ended July 31, Six Months Ended July 31,
2021 2020 2021 2020
Cash flows from operating activities:
Net income $ 317,084 $ 185,989 $ 544,615 $ 213,064
Adjustments to reconcile net income to net cash provided by operating activities:
Stock–based compensation expense 102,142 56,855 201,111 85,632
Amortization of deferred contract acquisition costs 41,626 24,494 79,392 40,781
Gains on strategic investments (32,076 ) "" (32,076 ) (2,538 )
Charitable donation of common stock "" 22,312 "" 23,312
Provision for accounts receivable allowances 10,537 11,091 14,592 14,959
Depreciation and amortization 12,028 6,475 22,691 11,814
Non–cash operating lease cost 4,359 2,349 8,633 4,597
Amortization on marketable securities 7,041 947 12,637 1,190
Other (6 ) (36 ) 264 838
Changes in operating assets and liabilities:
Accounts receivable (41,594 ) (54,425 ) (117,259 ) (196,926 )
Prepaid expenses and other assets (27,395 ) (4,649 ) (57,370 ) (53,729 )
Deferred contract acquisition costs (54,784 ) (88,936 ) (102,597 ) (213,790 )
Accounts payable 42,368 9,115 43,960 10,871
Accrued expenses and other liabilities 5,153 34,744 93,809 202,066
Deferred revenue 85,740 196,287 296,636 519,149
Operating lease liabilities, net (4,211 ) (1,266 ) (7,724 ) (979 )
Net cash provided by operating activities 468,012 401,346 1,001,314 660,311
Cash flows from investing activities:
Purchases of marketable securities (669,136 ) (277,336 ) (2,094,587 ) (484,882 )
Maturities of marketable securities 500,859 150,324 791,906 287,338
Sales of marketable securities 119,569 10,284 119,569 36,897
Purchases of property and equipment (12,975 ) (27,981 ) (92,049 ) (35,253 )
Purchases of strategic investments (80,400 ) "" (86,900 ) (13,000 )
Cash paid for acquisition, net of cash acquired (2,121 ) (26,486 ) (2,121 ) (26,486 )
Purchase of intangible assets "" (1,332 ) "" (1,494 )
Other "" "" "" 1,319
Net cash used in investing activities (144,204 ) (172,527 ) (1,364,182 ) (235,561 )
Cash flows from financing activities:
Proceeds from issuance of common stock for employee stock purchase plan 37,846 20,760 37,846 20,760
Proceeds from employee equity transactions to be remitted to employees and tax authorities, net 28,884 15,925 18,900 234,465
Proceeds from exercise of stock options 4,653 7,831 8,021 17,417
Other "" "" 337 ""
Net cash provided by financing activities 71,383 44,516 65,104 272,642
Net increase (decrease) in cash, cash equivalents, and restricted cash 395,191 273,335 (297,764 ) 697,392
Cash, cash equivalents, and restricted cash "" beginning of period 1,600,161 758,139 2,293,116 334,082
Cash, cash equivalents, and restricted cash "" end of period $ 1,995,352 $ 1,031,474 $ 1,995,352 $ 1,031,474



Zoom Video Communications, Inc.
Reconciliation of GAAP to Non–GAAP Measures
(Unaudited, in thousands, except share and per share amounts)

Three Months Ended July 31, Six Months Ended July 31,
2021 2020 2021 2020
GAAP income from operations $ 294,603 $ 188,104 $ 520,915 $ 211,489
Adjustments:
Stock–based compensation expense and related payroll taxes 116,742 61,602 221,117 91,848
Litigation settlements, net "" "" 66,916 ""
Acquisition–related expenses 13,320 4,942 16,604 4,942
Charitable donation of common stock "" 22,312 "" 23,312
Non–GAAP income from operations $ 424,665 $ 276,960 $ 825,552 $ 331,591
GAAP net income attributable to common stockholders $ 316,930 $ 185,742 $ 544,306 $ 212,759
Adjustments:
Stock–based compensation expense and related payroll taxes 116,742 61,602 221,117 91,848
Litigation settlements, net "" "" 66,916 ""
Gains on strategic investments (32,076 ) "" (32,076 ) ""
Acquisition–related expenses 13,320 4,942 16,604 4,942
Charitable donation of common stock "" 22,312 "" 23,312
Undistributed earnings attributable to participating securities 154 247 309 305
Non–GAAP net income $ 415,070 $ 274,845 $ 817,176 $ 333,166
Net income per share – basic and diluted:
GAAP net income per share – basic $ 1.07 $ 0.66 $ 1.85 $ 0.76
Non–GAAP net income per share – basic $ 1.40 $ 0.97 $ 2.77 $ 1.18
GAAP net income per share – diluted $ 1.04 $ 0.63 $ 1.78 $ 0.72
Non–GAAP net income per share – diluted $ 1.36 $ 0.92 $ 2.67 $ 1.12
GAAP and non–GAAP weighted–average shares used to compute net income per share – basic 295,712,675 282,850,805 294,769,619 281,394,901
GAAP and non–GAAP weighted–average shares used to compute net income per share – diluted 305,861,051 297,162,309 305,652,628 296,408,229
Net cash provided by operating activities $ 468,012 $ 401,346 $ 1,001,314 $ 660,311
Less:
Purchases of property and equipment (12,975 ) (27,981 ) (92,049 ) (35,253 )
Free cash flow (non–GAAP) $ 455,037 $ 373,365 $ 909,265 $ 625,058
Net cash used in investing activities $ (144,204 ) $ (172,527 ) $ (1,364,182 ) $ (235,561 )
Net cash provided by financing activities $ 71,383 $ 44,516 $ 65,104 $ 272,642


GLOBENEWSWIRE (Distribution ID 8317285)

Zoom Reports Financial Results for the Second Quarter of Fiscal Year 2022

  • Second quarter total revenue of $1,021.5 million, up 54% year over year
  • Number of customers contributing more than $100,000 in TTM revenue up 131% year over year
  • Second quarter GAAP operating margin of 28.8% and non–GAAP operating margin of 41.6%

SAN JOSE, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced financial results for the second fiscal quarter ended July 31, 2021.

"In Q2, we achieved our first billion dollar revenue quarter while delivering strong profitability and cash flow," said Zoom founder and CEO, Eric S. Yuan. "Q2 also marked several milestones on our expansion beyond the UC platform. We launched Zoom Apps, bringing over 50 apps directly into the Zoom experience, and Zoom Events, an all–in–one digital events service. Today we are a global brand counting over half a million customers with more than 10 employees, which we believe positions us extremely well to support organizations and individuals as they look to reimagine work, communications, and collaboration."

Second Quarter Fiscal Year 2022 Financial Highlights:

  • Revenue: Total revenue for the second quarter was $1,021.5 million, up 54% year over year.
  • Income from Operations and Operating Margin: GAAP income from operations for the second quarter was $294.6 million, up from $188.1 million in the second quarter of fiscal year 2021. After adjusting for stock–based compensation expense and related payroll taxes, acquisition–related expenses, and expenses related to charitable donation of common stock, non–GAAP income from operations for the second quarter was $424.7 million, up from $277.0 million in the second quarter of fiscal year 2021. For the second quarter, GAAP operating margin was 28.8% and non–GAAP operating margin was 41.6%.
  • Net Income and Diluted Net Income Per Share: GAAP net income attributable to common stockholders for the second quarter was $316.9 million, or $1.04 per share, up from $185.7 million, or $0.63 per share in the second quarter of fiscal year 2021.

    Non–GAAP net income for the quarter was $415.1 million, after adjusting for stock–based compensation expense and related payroll taxes, acquisition–related expenses, gains on strategic investments, undistributed earnings attributable to participating securities, and expenses related to charitable donation of common stock. Non–GAAP net income per share was $1.36. In the second quarter of fiscal year 2021, non–GAAP net income was $274.8 million, or $0.92 per share.

  • Cash and Marketable Securities: Total cash, cash equivalents, and marketable securities, excluding restricted cash, as of July 31, 2021 was $5.1 billion.
  • Cash Flow: Net cash provided by operating activities was $468.0 million for the second quarter, compared to $401.3 million in the second quarter of fiscal year 2021. Free cash flow, which is net cash provided by operating activities less purchases of property and equipment, was $455.0 million, compared to $373.4 million in the second quarter of fiscal year 2021.

Customer Metrics: Drivers of total revenue included acquiring new customers and expanding across existing customers. At the end of the second quarter of fiscal year 2022, Zoom had:

  • 2,278 customers contributing more than $100,000 in trailing 12 months revenue, up approximately 131% from the same quarter last fiscal year.
  • Approximately 504,900 customers with more than 10 employees, up approximately 36% from the same quarter last fiscal year.
  • A trailing 12–month net dollar expansion rate in customers with more than 10 employees above 130% for the 13th consecutive quarter.

Financial Outlook: Zoom is providing the following guidance for its third quarter fiscal year 2022 and its full fiscal year 2022.

  • Third Quarter Fiscal Year 2022: Total revenue is expected to be between $1.015 billion and $1.020 billion and non–GAAP income from operations is expected to be between $340.0 million and $345.0 million. Non–GAAP diluted EPS is expected to be between $1.07 and $1.08 with approximately 309 million non–GAAP weighted average shares outstanding.
  • Full Fiscal Year 2022: Total revenue is expected to be between $4.005 billion and $4.015 billion. Non–GAAP income from operations is expected to be between $1.500 billion and $1.510 billion. Non–GAAP diluted EPS is expected to be between $4.75 and $4.79 with approximately 308 million non–GAAP weighted average shares outstanding.

Additional information on Zoom's reported results, including a reconciliation of the non–GAAP results to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non–GAAP guidance measures to corresponding GAAP measures is not available on a forward–looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Zoom's results computed in accordance with GAAP.

A supplemental financial presentation and other information can be accessed through Zoom's investor relations website at investors.zoom.us.

Zoom Video Earnings Call
Zoom will host a Zoom Video Webinar for investors on August 30, 2021 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the company's financial results and business highlights. Investors are invited to join the Zoom Video Webinar by visiting: https://investors.zoom.us/

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Forward–Looking Statements
This press release contains express and implied "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook for the third quarter of fiscal year 2022 and full fiscal year 2022, Zoom's growth strategy and business aspirations to support organizations and people on multiple fronts as they look to reimagine work, communications and collaboration. In some cases, you can identify forward–looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward–looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including: declines in new customers and hosts, renewals or upgrades, difficulties in evaluating our prospects and future results of operations given our limited operating history, competition from other providers of communications platforms, continued uncertainty regarding the extent and duration of the impact of COVID–19 and the responses of government and private industry thereto, including the potential effect on our user growth rate once the impact of the COVID–19 pandemic tapers, particularly as a vaccine becomes widely available, and users return to work or school or are otherwise no longer subject to shelter–in–place mandates, as well as the impact of COVID–19 on the overall economic environment, any or all of which will have an impact on demand for remote work solutions for businesses as well as overall distributed, face–to–face interactions and collaboration using Zoom, delays or outages in services from our co–located data centers, and failures in internet infrastructure or interference with broadband access which could cause current or potential users to believe that our systems are unreliable. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward–looking statements are included under the caption "Risk Factors" and elsewhere in our most recent filings with the Securities and Exchange Commission (the "SEC"), including our quarterly report on Form 10–Q for the fiscal quarter ended April 30, 2021. Forward–looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward–looking statements to reflect events or circumstances after the date they were made, except as required by law.

Non–GAAP Financial Measures
Zoom has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Zoom uses these non–GAAP financial measures internally in analyzing its financial results and believes that use of these non–GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing Zoom's financial results with other companies in its industry, many of which present similar non–GAAP financial measures.

Non–GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with Zoom's condensed consolidated financial statements prepared in accordance with GAAP. A reconciliation of Zoom's historical non–GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.

Non–GAAP Income From Operations and Non–GAAP Operating Margins. Zoom defines non–GAAP income from operations as income from operations excluding stock–based compensation expense and related payroll taxes, expenses related to charitable donation of common stock, acquisition–related expenses, and litigation settlements, net. Zoom excludes stock–based compensation expense and expenses related to charitable donation of common stock because they are non–cash in nature and excluding these expenses provides meaningful supplemental information regarding Zoom's operational performance and allows investors the ability to make more meaningful comparisons between Zoom's operating results and those of other companies. Zoom excludes the amount of employer payroll taxes related to employee stock plans, which is a cash expense, in order for investors to see the full effect that excluding stock–based compensation expense had on Zoom's operating results. In particular, this expense is dependent on the price of our common stock and other factors that are beyond our control and do not correlate to the operation of the business. Zoom views acquisition–related expenses when applicable, such as amortization of acquired intangible assets, transaction costs, and acquisition–related retention payments that are directly related to business combinations as events that are not necessarily reflective of operational performance during a period. Zoom excludes significant litigation settlements, net of amounts covered by insurance, that we deem not to be in the ordinary course of our business. In particular, Zoom believes the consideration of measures that exclude such expenses can assist in the comparison of operational performance in different periods which may or may not include such expenses and assist in the comparison with the results of other companies in the industry.

Non–GAAP Net Income and Non–GAAP Net Income Per Share, Basic and Diluted. Zoom defines non–GAAP net income and non–GAAP net income per share, basic and diluted, as GAAP net income attributable to common stockholders and GAAP net income per share attributable to common stockholders, basic and diluted, respectively, adjusted to exclude stock–based compensation expense and related payroll taxes, expenses related to charitable donation of common stock, acquisition–related expenses, litigation settlements, net, gains on strategic investments, and undistributed earnings attributable to participating securities. Zoom excludes gains on strategic investments because given the size and volatility in the ongoing adjustments to the valuation of our strategic investments, we believe that excluding these gains or losses facilitates a more meaningful evaluation of our operational performance. Zoom excludes undistributed earnings attributable to participating securities because they are considered by management to be outside of Zoom's core operating results, and excluding them provides investors and management with greater visibility to the underlying performance of Zoom's business operations, facilitates comparison of its results with other periods and may also facilitate comparison with the results of other companies in the industry.

In order to calculate non–GAAP net income per share, basic and diluted, Zoom uses a non–GAAP weighted–average share count. Zoom defines non–GAAP weighted–average shares used to compute non–GAAP net income per share, basic and diluted, as GAAP weighted average shares used to compute net income per share attributable to common stockholders, basic and diluted, adjusted to reflect the common stock issued in connection with the IPO, including the concurrent private placement, that are outstanding as of the end of the period as if they were outstanding as of the beginning of the period for comparability.

Free Cash Flow. Zoom defines free cash flow as GAAP net cash provided by operating activities less purchases of property and equipment. Zoom considers free cash flow to be a liquidity measure that provides useful information to management and investors regarding net cash provided by operating activities and cash used for investments in property and equipment required to maintain and grow the business.

Customer Metrics
Zoom defines a customer as a separate and distinct buying entity, which can be a single paid host or an organization of any size (including a distinct unit of an organization) that has multiple paid hosts.

Zoom calculates net dollar expansion rate as of a period end by starting with the annual recurring revenue ("ARR") from all customers with more than 10 employees as of 12 months prior ("Prior Period ARR"). Zoom defines ARR as the annualized revenue run rate of subscription agreements from all customers at a point in time. We then calculate the ARR from these customers as of the current period end ("Current Period ARR"), which includes any upsells, contraction, and attrition. Zoom divides the Current Period ARR by the Prior Period ARR to arrive at the net dollar expansion rate. For the trailing 12 months calculation, Zoom takes an average of the net dollar expansion rate over the trailing 12 months.

Press Relations

Colleen Rodriguez
Global Public Relations Lead for Zoom
press@zoom.us

Investor Relations

Tom McCallum
Head of Investor Relations for Zoom
investors@zoom.us



Zoom Video Communications, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)

As of
July 31,
2021
January 31,
2021
Assets
Current assets:
Cash and cash equivalents $ 1,931,370 $ 2,240,303
Marketable securities 3,174,029 2,004,410
Accounts receivable, net 395,266 294,703
Deferred contract acquisition costs, current 162,126 136,630
Prepaid expenses and other current assets 172,288 116,819
Total current assets 5,835,079 4,792,865
Deferred contract acquisition costs, noncurrent 154,971 157,262
Property and equipment, net 193,852 149,924
Operating lease right–of–use assets 91,087 97,649
Strategic investments 137,795 18,668
Goodwill 26,247 24,340
Other assets, noncurrent 69,562 57,285
Total assets $ 6,508,593 $ 5,297,993
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 49,762 $ 8,664
Accrued expenses and other current liabilities 482,162 393,018
Deferred revenue, current 1,154,449 858,284
Total current liabilities 1,686,373 1,259,966
Deferred revenue, noncurrent 23,579 25,211
Operating lease liabilities, noncurrent 83,009 90,415
Other liabilities, noncurrent 57,884 61,634
Total liabilities 1,850,845 1,437,226
Stockholders' equity:
Preferred stock "" ""
Common stock 296 292
Additional paid–in capital 3,440,222 3,187,168
Accumulated other comprehensive income 147 839
Retained earnings 1,217,083 672,468
Total stockholders' equity 4,657,748 3,860,767
Total liabilities and stockholders' equity $ 6,508,593 $ 5,297,993

Note: The amount of unbilled accounts receivable included within accounts receivable, net on the condensed consolidated balance sheets was $35.4 million and $24.6 million as of July 31, 2021 and January 31, 2021, respectively.



Zoom Video Communications, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share amounts)

Three Months Ended July 31, Six Months Ended July 31,
2021 2020 2021 2020
Revenue $ 1,021,495 $ 663,520 $ 1,977,732 $ 991,687
Cost of revenue 261,256 192,271 526,250 295,978
Gross profit 760,239 471,249 1,451,482 695,709
Operating expenses:
Research and development 82,311 42,734 147,486 69,123
Sales and marketing 271,179 159,173 516,846 280,729
General and administrative 112,146 81,238 266,235 134,368
Total operating expenses 465,636 283,145 930,567 484,220
Income from operations 294,603 188,104 520,915 211,489
Gains on strategic investments 32,076 "" 32,076 2,538
Interest income and other, net (2,795 ) 2,081 (176 ) 5,333
Income before provision for income taxes 323,884 190,185 552,815 219,360
Provision for income taxes 6,800 4,196 8,200 6,296
Net income 317,084 185,989 544,615 213,064
Undistributed earnings attributable to participating securities (154 ) (247 ) (309 ) (305 )
Net income attributable to common stockholders $ 316,930 $ 185,742 $ 544,306 $ 212,759
Net income per share attributable to common stockholders:
Basic $ 1.07 $ 0.66 $ 1.85 $ 0.76
Diluted $ 1.04 $ 0.63 $ 1.78 $ 0.72
Weighted–average shares used in computing net income per share attributable to common stockholders:
Basic 295,712,675 282,850,805 294,769,619 281,394,901
Diluted 305,861,051 297,162,309 305,652,628 296,408,229



Zoom Video Communications, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

Three Months Ended July 31, Six Months Ended July 31,
2021 2020 2021 2020
Cash flows from operating activities:
Net income $ 317,084 $ 185,989 $ 544,615 $ 213,064
Adjustments to reconcile net income to net cash provided by operating activities:
Stock–based compensation expense 102,142 56,855 201,111 85,632
Amortization of deferred contract acquisition costs 41,626 24,494 79,392 40,781
Gains on strategic investments (32,076 ) "" (32,076 ) (2,538 )
Charitable donation of common stock "" 22,312 "" 23,312
Provision for accounts receivable allowances 10,537 11,091 14,592 14,959
Depreciation and amortization 12,028 6,475 22,691 11,814
Non–cash operating lease cost 4,359 2,349 8,633 4,597
Other (6 ) (36 ) 264 838
Changes in operating assets and liabilities:
Accounts receivable (41,594 ) (54,425 ) (117,259 ) (196,926 )
Prepaid expenses and other assets (27,395 ) (4,649 ) (57,370 ) (53,729 )
Deferred contract acquisition costs (54,784 ) (88,936 ) (102,597 ) (213,790 )
Accounts payable 42,368 9,115 43,960 10,871
Accrued expenses and other liabilities 5,153 34,744 93,809 202,066
Deferred revenue 85,740 196,287 296,636 519,149
Operating lease liabilities, net (4,211 ) (1,266 ) (7,724 ) (979 )
Net cash provided by operating activities 468,012 401,346 1,001,314 660,311
Cash flows from investing activities:
Purchases of marketable securities (669,136 ) (277,336 ) (2,094,587 ) (484,882 )
Maturities of marketable securities 500,859 150,324 791,906 287,338
Sales of marketable securities 119,569 10,284 119,569 36,897
Purchases of property and equipment (12,975 ) (27,981 ) (92,049 ) (35,253 )
Purchases of strategic investments (80,400 ) "" (86,900 ) (13,000 )
Cash paid for acquisition, net of cash acquired (2,121 ) (26,486 ) (2,121 ) (26,486 )
Purchase of intangible assets "" (1,332 ) "" (1,494 )
Other "" "" "" 1,319
Net cash used in investing activities (144,204 ) (172,527 ) (1,364,182 ) (235,561 )
Cash flows from financing activities:
Proceeds from issuance of common stock for employee stock purchase plan 37,846 20,760 37,846 20,760
Proceeds from employee equity transactions to be remitted to employees and tax authorities, net 28,884 15,925 18,900 234,465
Proceeds from exercise of stock options 4,653 7,831 8,021 17,417
Other "" "" 337 ""
Net cash provided by financing activities 71,383 44,516 65,104 272,642
Net increase (decrease) in cash, cash equivalents, and restricted cash 395,191 273,335 (297,764 ) 697,392
Cash, cash equivalents, and restricted cash "" beginning of period 1,600,161 758,139 2,293,116 334,082
Cash, cash equivalents, and restricted cash "" end of period $ 1,995,352 $ 1,031,474 $ 1,995,352 $ 1,031,474



Zoom Video Communications, Inc.
Reconciliation of GAAP to Non–GAAP Measures
(Unaudited, in thousands, except share and per share amounts)

Three Months Ended July 31, Six Months Ended July 31,
2021 2020 2021 2020
GAAP income from operations $ 294,603 $ 188,104 $ 520,915 $ 211,489
Adjustments:
Stock–based compensation expense and related payroll taxes 116,742 61,602 221,117 91,848
Litigation settlements, net "" "" 66,916 ""
Acquisition–related expenses 13,320 4,942 16,604 4,942
Charitable donation of common stock "" 22,312 "" 23,312
Non–GAAP income from operations $ 424,665 $ 276,960 $ 825,552 $ 331,591
GAAP net income attributable to common stockholders $ 316,930 $ 185,742 $ 544,306 $ 212,759
Adjustments:
Stock–based compensation expense and related payroll taxes 116,742 61,602 221,117 91,848
Litigation settlements, net "" "" 66,916 ""
Gains on strategic investments (32,076 ) "" (32,076 ) ""
Acquisition–related expenses 13,320 4,942 16,604 4,942
Charitable donation of common stock "" 22,312 "" 23,312
Undistributed earnings attributable to participating securities 154 247 309 305
Non–GAAP net income $ 415,070 $ 274,845 $ 817,176 $ 333,166
Net income per share – basic and diluted:
GAAP net income per share – basic $ 1.07 $ 0.66 $ 1.85 $ 0.76
Non–GAAP net income per share – basic $ 1.40 $ 0.97 $ 2.77 $ 1.18
GAAP net income per share – diluted $ 1.04 $ 0.63 $ 1.78 $ 0.72
Non–GAAP net income per share – diluted $ 1.36 $ 0.92 $ 2.67 $ 1.12
GAAP and non–GAAP weighted–average shares used to compute net income per share – basic 295,712,675 282,850,805 294,769,619 281,394,901
GAAP and non–GAAP weighted–average shares used to compute net income per share – diluted 305,861,051 297,162,309 305,652,628 296,408,229
Net cash provided by operating activities $ 468,012 $ 401,346 $ 1,001,314 $ 660,311
Less:
Purchases of property and equipment (12,975 ) (27,981 ) (92,049 ) (35,253 )
Free cash flow (non–GAAP) $ 455,037 $ 373,365 $ 909,265 $ 625,058
Net cash used in investing activities $ (144,204 ) $ (172,527 ) $ (1,364,182 ) $ (235,561 )
Net cash provided by financing activities $ 71,383 $ 44,516 $ 65,104 $ 272,642


GLOBENEWSWIRE (Distribution ID 8317285)

Zoom Video Communications to Release Financial Results for the Second Quarter of Fiscal Year 2022

SAN JOSE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), a leading provider of frictionless enterprise communications, today announced it will release its financial results for the second quarter of fiscal year 2022 on Monday, August 30, 2021, after the market closes.

A live Zoom Video Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom's investor relations website at https://investors.zoom.us. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Public Relations
Colleen Rodriguez
Global PR Lead for Zoom
press@zoom.us

Investor Relations
Tom McCallum
Head of Investor Relations for Zoom
408.675.6738
investors@zoom.us


GLOBENEWSWIRE (Distribution ID 8301140)

Zoom Reports Financial Results for the First Quarter of Fiscal Year 2022

  • First quarter total revenue of $956.2 million, up 191% year over year
  • Number of customers contributing more than $100,000 in TTM revenue up 160% year over year
  • Approximately 497,000 customers with more than 10 employees, up 87% year over year

SAN JOSE, Calif., June 01, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced financial results for the first fiscal quarter ended April 30, 2021.

"We kicked off the fiscal year with a very strong first quarter, posting 191% total year–over–year revenue growth combined with strong profitability and cash flow. Our steadfast commitment to empowering customers to work and learn from anywhere with our expansive, innovative, and frictionless video communications platform continued to drive our results. With this solid start, we are pleased to raise our total guidance range to $3.975 billion to $3.990 billion for the full fiscal year," said Zoom founder and CEO, Eric S. Yuan. "We have also opened our technology portfolio to developers through our powerful video SDK and to businesses to expand their reach through Zoom Events. Work is no longer a place, it's a space where Zoom serves to empower your teams to connect and bring their best ideas to life. We are energized to help lead the evolution to hybrid work that allows greater flexibility, productivity, and happiness to both in–person and virtual connections."

First Quarter Fiscal Year 2022 Financial Highlights:

  • Revenue: Total revenue for the first quarter was $956.2 million, up 191% year over year.
  • Income from Operations and Operating Margin: GAAP income from operations for the first quarter was $226.3 million, up from $23.4 million in the first quarter of fiscal year 2021. After adjusting for stock–based compensation expense and related payroll taxes, acquisition–related expenses, and litigation settlements, net, non–GAAP income from operations for the first quarter was $400.9 million, up from $54.6 million in the first quarter of fiscal year 2021. For the first quarter, GAAP operating margin was 23.7% and non–GAAP operating margin was 41.9%.
  • Net Income and Net Income Per Share: GAAP net income attributable to common stockholders for the first quarter was $227.4 million, or $0.74 per share, up from $27.0 million, or $0.09 per share in the first quarter of fiscal year 2021.

    Non–GAAP net income for the quarter was $402.1 million, after adjusting for stock–based compensation expense and related payroll taxes, acquisition–related expenses, litigation settlements, net, and undistributed earnings attributable to participating securities. Non–GAAP net income per share was $1.32. In the first quarter of fiscal year 2021, non–GAAP net income was $58.3 million, or $0.20 per share.

  • Cash and Marketable Securities: Total cash, cash equivalents, and marketable securities, excluding restricted cash, as of April 30, 2021 was $4.7 billion.
  • Cash Flow: Net cash provided by operating activities was $533.3 million for the first quarter, compared to $259.0 million in the first quarter of fiscal year 2021. Free cash flow, which is net cash provided by operating activities less purchases of property and equipment, was $454.2 million, compared to $251.7 million in the first quarter of fiscal year 2021.

Customer Metrics: Drivers of total revenue included acquiring new customers and expanding across existing customers. At the end of the first quarter of fiscal year 2022, Zoom had:

  • Approximately 497,000 customers with more than 10 employees, up approximately 87% from the same quarter last fiscal year.
  • 1,999 customers contributing more than $100,000 in trailing 12 months revenue, up approximately 160% from the same quarter last fiscal year.
  • A trailing 12–month net dollar expansion rate in customers with more than 10 employees above 130% for the 12th consecutive quarter.

Financial Outlook: Zoom is providing the following guidance for its second quarter fiscal year 2022 and its full fiscal year 2022.

  • Second Quarter Fiscal Year 2022: Total revenue is expected to be between $985.0 million and $990.0 million and non–GAAP income from operations is expected to be between $355.0 million and $360.0 million. Non–GAAP diluted EPS is expected to be between $1.14 and $1.15 with approximately 311 million non–GAAP weighted average shares outstanding.
  • Full Fiscal Year 2022: Total revenue is expected to be between $3.975 billion and $3.990 billion. Non–GAAP income from operations is expected to be between $1.425 billion and $1.440 billion. Non–GAAP diluted EPS is expected to be between $4.56 and $4.61 with approximately 311 million non–GAAP weighted average shares outstanding.

Additional information on Zoom's reported results, including a reconciliation of the non–GAAP results to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non–GAAP guidance measures to corresponding GAAP measures is not available on a forward–looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Zoom's results computed in accordance with GAAP.

A supplemental financial presentation and other information can be accessed through Zoom's investor relations website at investors.zoom.us.

Zoom Video Earnings Call

Zoom will host a Zoom Video Webinar for investors on June 1, 2021 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the company's financial results and business highlights. Investors are invited to join the Zoom Video Webinar by visiting: https://investors.zoom.us/

About Zoom

Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Forward–Looking Statements

This press release contains express and implied "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook for the second quarter of fiscal year 2022 and full fiscal year 2022, Zoom's growth strategy and business aspirations to lead the evolution to hybrid work. In some cases, you can identify forward–looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward–looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including: declines in new customers and hosts, renewals or upgrades, difficulties in evaluating our prospects and future results of operations given our limited operating history, competition from other providers of communications platforms, continued uncertainty regarding the extent and duration of the impact of COVID–19 and the responses of government and private industry thereto, including the potential effect on our user growth rate once the impact of the COVID–19 pandemic tapers, particularly as a vaccine becomes widely available, and users return to work or school or are otherwise no longer subject to shelter–in–place mandates, as well as the impact of COVID–19 on the overall economic environment, any or all of which will have an impact on demand for remote work solutions for businesses as well as overall distributed, face–to–face interactions and collaboration using Zoom, delays or outages in services from our co–located data centers, and failures in internet infrastructure or interference with broadband access which could cause current or potential users to believe that our systems are unreliable. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward–looking statements are included under the caption "Risk Factors" and elsewhere in our most recent filings with the Securities and Exchange Commission (the "SEC"), including our annual report on Form 10–K for the fiscal year ended January 31, 2021. Forward–looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward–looking statements to reflect events or circumstances after the date they were made, except as required by law.

Non–GAAP Financial Measures

Zoom has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Zoom uses these non–GAAP financial measures internally in analyzing its financial results and believes that use of these non–GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing Zoom's financial results with other companies in its industry, many of which present similar non–GAAP financial measures.

Non–GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with Zoom's condensed consolidated financial statements prepared in accordance with GAAP. A reconciliation of Zoom's historical non–GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.

Non–GAAP Income From Operations and Non–GAAP Operating Margins. Zoom defines non–GAAP income from operations as income from operations excluding stock–based compensation expense and related payroll taxes, expenses related to charitable donation of common stock, acquisition–related expenses, and litigation settlements, net. Zoom excludes stock–based compensation expense and expenses related to charitable donation of common stock because they are non–cash in nature and excluding these expenses provides meaningful supplemental information regarding Zoom's operational performance and allows investors the ability to make more meaningful comparisons between Zoom's operating results and those of other companies. Zoom excludes the amount of employer payroll taxes related to employee stock plans, which is a cash expense, in order for investors to see the full effect that excluding stock–based compensation expense had on Zoom's operating results. In particular, this expense is dependent on the price of our common stock and other factors that are beyond our control and do not correlate to the operation of the business. Zoom views acquisition–related expenses when applicable, such as amortization of acquired intangible assets, transaction costs, and acquisition–related retention payments that are directly related to business combinations as events that are not necessarily reflective of operational performance during a period. Zoom excludes significant litigation settlements, net of amounts covered by insurance, that we deem not to be in the ordinary course of our business. In particular, Zoom believes the consideration of measures that exclude such expenses can assist in the comparison of operational performance in different periods which may or may not include such expenses and assist in the comparison with the results of other companies in the industry.

Non–GAAP Net Income and Non–GAAP Net Income Per Share, Basic and Diluted. Zoom defines non–GAAP net income and non–GAAP net income per share, basic and diluted, as GAAP net income attributable to common stockholders and GAAP net income per share attributable to common stockholders, basic and diluted, respectively, adjusted to exclude stock–based compensation expense and related payroll taxes, expenses related to charitable donation of common stock, acquisition–related expenses, litigation settlements, net, and undistributed earnings attributable to participating securities. Zoom excludes undistributed earnings attributable to participating securities because they are considered by management to be outside of Zoom's core operating results, and excluding them provides investors and management with greater visibility to the underlying performance of Zoom's business operations, facilitates comparison of its results with other periods and may also facilitate comparison with the results of other companies in the industry.

In order to calculate non–GAAP net income per share, basic and diluted, Zoom uses a non–GAAP weighted–average share count. Zoom defines non–GAAP weighted–average shares used to compute non–GAAP net income per share, basic and diluted, as GAAP weighted average shares used to compute net income per share attributable to common stockholders, basic and diluted, adjusted to reflect the common stock issued in connection with the IPO, including the concurrent private placement, that are outstanding as of the end of the period as if they were outstanding as of the beginning of the period for comparability.

Free Cash Flow. Zoom defines free cash flow as GAAP net cash provided by operating activities less purchases of property and equipment. Zoom considers free cash flow to be a liquidity measure that provides useful information to management and investors regarding net cash provided by operating activities and cash used for investments in property and equipment required to maintain and grow the business.

Customer Metrics

Zoom defines a customer as a separate and distinct buying entity, which can be a single paid host or an organization of any size (including a distinct unit of an organization) that has multiple paid hosts.

Zoom calculates net dollar expansion rate as of a period end by starting with the annual recurring revenue ("ARR") from all customers with more than 10 employees as of 12 months prior ("Prior Period ARR"). Zoom defines ARR as the annualized revenue run rate of subscription agreements from all customers at a point in time. We then calculate the ARR from these customers as of the current period end ("Current Period ARR"), which includes any upsells, contraction, and attrition. Zoom divides the Current Period ARR by the Prior Period ARR to arrive at the net dollar expansion rate. For the trailing 12 months calculation, Zoom takes an average of the net dollar expansion rate over the trailing 12 months.

Press Relations

Colleen Rodriguez
Global Public Relations Lead for Zoom
press@zoom.us

Investor Relations

Tom McCallum
Head of Investor Relations for Zoom
investors@zoom.us


Zoom Video Communications, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)

As of
April 30,
2021
January 31,
2021
Assets
Current assets:
Cash and cash equivalents $ 1,557,270 $ 2,240,303
Marketable securities 3,132,309 2,004,410
Accounts receivable, net 366,346 294,703
Deferred contract acquisition costs, current 148,645 136,630
Prepaid expenses and other current assets 136,326 116,819
Total current assets 5,340,896 4,792,865
Deferred contract acquisition costs, noncurrent 155,295 157,262
Property and equipment, net 192,410 149,924
Operating lease right–of–use assets 93,780 97,649
Goodwill 24,340 24,340
Other assets, noncurrent 81,890 75,953
Total assets $ 5,888,611 $ 5,297,993
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 8,324 $ 8,664
Accrued expenses and other current liabilities 450,678 393,018
Deferred revenue, current 1,069,334 858,284
Total current liabilities 1,528,336 1,259,966
Deferred revenue, noncurrent 25,089 25,211
Operating lease liabilities, noncurrent 86,433 90,415
Other liabilities, noncurrent 56,020 61,634
Total liabilities 1,695,878 1,437,226
Stockholders' equity:
Preferred stock "" ""
Common stock 293 292
Additional paid–in capital 3,292,241 3,187,168
Accumulated other comprehensive income 200 839
Retained earnings 899,999 672,468
Total stockholders' equity 4,192,733 3,860,767
Total liabilities and stockholders' equity $ 5,888,611 $ 5,297,993

Note: The amount of unbilled accounts receivable included within accounts receivable, net on the condensed consolidated balance sheets was $28.8 million and $24.6 million as of April 30, 2021 and January 31, 2021, respectively.


Zoom Video Communications, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share amounts)

Three Months Ended April 30,
2021 2020
Revenue $ 956,237 $ 328,167
Cost of revenue 264,994 103,707
Gross profit 691,243 224,460
Operating expenses:
Research and development 65,175 26,389
Sales and marketing 245,667 121,556
General and administrative 154,089 53,130
Total operating expenses 464,931 201,075
Income from operations 226,312 23,385
Interest income and other, net 2,619 5,790
Income before provision for income taxes 228,931 29,175
Provision for income taxes 1,400 2,100
Net income 227,531 27,075
Undistributed earnings attributable to participating securities (148 ) (39 )
Net income attributable to common stockholders $ 227,383 $ 27,036
Net income per share attributable to common stockholders:
Basic $ 0.77 $ 0.10
Diluted $ 0.74 $ 0.09
Weighted–average shares used in computing net income per share attributable to common stockholders:
Basic 293,794,778 279,891,111
Diluted 305,412,419 295,184,958


Zoom Video Communications, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

Three Months Ended April 30,
2021 2020
Cash flows from operating activities:
Net income $ 227,531 $ 27,075
Adjustments to reconcile net income to net cash provided by operating activities:
Stock–based compensation expense 98,969 28,777
Amortization of deferred contract acquisition costs 37,766 16,287
Charitable donation of common stock "" 1,000
Provision for accounts receivable allowances 4,055 3,868
Depreciation and amortization 10,663 5,339
Non–cash operating lease cost 4,274 2,248
Other 5,866 (1,421 )
Changes in operating assets and liabilities:
Accounts receivable (75,665 ) (142,501 )
Prepaid expenses and other assets (29,975 ) (49,080 )
Deferred contract acquisition costs (47,813 ) (124,854 )
Accounts payable 1,592 1,756
Accrued expenses and other liabilities 88,656 167,322
Deferred revenue 210,896 322,862
Operating lease liabilities, net (3,513 ) 287
Net cash provided by operating activities 533,302 258,965
Cash flows from investing activities:
Purchases of marketable securities (1,425,451 ) (207,546 )
Maturities of marketable securities 291,047 137,014
Sales of marketable securities "" 26,613
Purchases of property and equipment (79,074 ) (7,272 )
Purchase of equity investment "" (8,000 )
Purchase of convertible promissory note (6,500 ) (5,000 )
Purchase of intangible assets "" (162 )
Other "" 1,319
Net cash used in investing activities (1,219,978 ) (63,034 )
Cash flows from financing activities:
Proceeds from employee equity transactions (remitted) to be remitted to employees and tax authorities, net (9,984 ) 218,540
Proceeds from exercise of stock options 3,368 9,586
Other 337 ""
Net cash (used in) provided by financing activities (6,279 ) 228,126
Net (decrease) increase in cash, cash equivalents, and restricted cash (692,955 ) 424,057
Cash, cash equivalents, and restricted cash "" beginning of period 2,293,116 334,082
Cash, cash equivalents, and restricted cash "" end of period $ 1,600,161 $ 758,139


Zoom Video Communications, Inc.
Reconciliation of GAAP to Non–GAAP Measures
(Unaudited, in thousands, except share and per share amounts)

Three Months Ended April 30,
2021 2020
GAAP income from operations $ 226,312 $ 23,385
Add:
Stock–based compensation expense and related payroll taxes 104,375 30,246
Litigation settlements, net 66,916 ""
Acquisition–related expenses 3,284 ""
Charitable donation of common stock "" 1,000
Non–GAAP income from operations $ 400,887 $ 54,631
GAAP net income attributable to common stockholders $ 227,383 $ 27,036
Add:
Stock–based compensation expense and related payroll taxes 104,375 30,246
Litigation settlements, net 66,916 ""
Acquisition–related expenses 3,284 ""
Charitable donation of common stock "" 1,000
Undistributed earnings attributable to participating securities 148 39
Non–GAAP net income $ 402,106 $ 58,321
Net income per share – basic and diluted:
GAAP net income per share – basic $ 0.77 $ 0.10
Non–GAAP net income per share – basic $ 1.37 $ 0.21
GAAP net income per share – diluted $ 0.74 $ 0.09
Non–GAAP net income per share – diluted $ 1.32 $ 0.20
GAAP and non–GAAP weighted–average shares used to compute net income per share – basic 293,794,778 279,891,111
GAAP and non–GAAP weighted–average shares used to compute net income per share – diluted 305,412,419 295,184,958
Net cash provided by operating activities $ 533,302 $ 258,965
Less:
Purchases of property and equipment (79,074 ) (7,272 )
Free cash flow (non–GAAP) $ 454,228 $ 251,693
Net cash used in investing activities $ (1,219,978 ) $ (63,034 )
Net cash (used in) provided by financing activities $ (6,279 ) $ 228,126


GLOBENEWSWIRE (Distribution ID 8246837)

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

"' Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3–Month Primary Endpoint; Final Data Including BMD Expected Q2:21 "'

"' Entera's Oral Delivery Platform Shows Potential in Indications Including GLP–2 and Human Growth Hormone "'

"' Company to Host Conference Call and Webcast Today at 8:30 a.m. ET "'

BOSTON and JERUSALEM, May 20, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the quarter ended March 31, 2021.

First Quarter 2021 and Recent Highlights

  • 3–Month Primary Efficacy Endpoint Achieved in Phase 2 Trial of EB613 in Osteoporosis: EB613, an orally delivered human parathyroid hormone (1–34) or PTH, is positioned to be the first oral bone building (osteoanabolic) treatment for osteoporosis. The Phase 2 study's efficacy endpoints include an evaluation of biomarker data after 3 and 6 months of treatment and bone mineral density data (BMD) after 6 months of treatment. The study met its primary 3–month endpoint. Subjects in the 2.5 mg dose group had a significant (p<0.04) increase in bone formation biomarkers P1NP (primary endpoint) and Osteocalcin (p<0.006) from baseline compared to placebo. Patients in the 2.5 mg dose group also had a significant (p<0.015) reduction in CTX, a bone resorption marker correlated with a reduction in the breakdown of bone and an important factor for a potential increase in BMD. The last patient enrolled in the study has completed the last visit and final data analyses including 6–month BMD data are expected Q2 2021.

    Assuming positive final results from this trial, Entera intends to meet with the FDA to discuss the design of a pivotal Phase 3 non–inferiority trial examining the increase in spine bone mineral density of EB613 compared to the increase observed with Forteo (SC PTH 1–34) and confirm the potential for approval under the 505 (b)(2) regulatory pathway.

  • Positive Data from EB612 Phase 2a Clinical Trial in Hypoparathyroidism (HypoPT) Published: An article titled "Safety and Efficacy of Oral Human Parathyroid Hormone (1–34) in Hypoparathyroidism: An Open–Label Study" published in The Journal of Bone and Mineral Research Results reported results from Entera's Phase 2a clinical study which achieved its primary and secondary endpoints. Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin–adjusted calcium, and reduction of serum phosphate. The Company expects to initiate a Phase 2b HypoPT trial in 2022.
  • Oral Large Molecule Delivery Platform Shows Potential in GLP–2 and hGH: Based on positive pre–clinical data, Entera initiated a research program for an oral glucagon–like peptide–2 (GLP–2) analog which may support a new class of drugs to treat a broad range of gastrointestinal and metabolic diseases. Currently, the only GLP–2 analog on the market is a once–daily injection for the treatment of short bowel syndrome with reported global sales of $574 million in 2019. Showing efficacy in yet another indication, Entera delivered a poster presentation titled "Pharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice" at the 31st Annual European Pharma Congress in April. Plasma samples analyzed in the preclinical study showed substantial gastrointestinal absorption of Entera's oral hGH formulation and significant systemic exposure to the drug. Prescription hGH, a widely used therapeutic molecule, is currently only administered via subcutaneous injection for the treatment of growth hormone deficiency as well as other indications, a $3.7 billion market in 2020. Entera is currently evaluating different strategies to advance the oral GLP–2 and hGH programs into clinical development including through industry partnerships.
  • Robust Balance Sheet: Entera strengthened its balance sheet which currently has a cash position of over $16 million as of March 31, 2021 giving the Company an expected cash runway into the second quarter of 2022.

"We were very pleased with the 3–month efficacy data for EB613 in the treatment of osteoporosis and look forward to announcing final 6 month BMD data this quarter. Despite the challenges of COVID, I am grateful to the patients, investigators and team's focus to successfully executing the study. A safe and effective oral PTH alternative is expected to substantially increase patient compliance and participation, thereby expanding the treatment market and offering a higher quality of life for people living with osteoporosis," stated Entera CEO Spiros Jamas. "Having identified new indications in which our formulations are showing preclinical efficacy, we are expanding the value of our platform and assets."

Financial Results for the Quarter Ended March 31, 2021

Revenues for the quarter ended March 31, 2021 were $157,000 compared to $42,000 for the quarter ended March 31, 2020, with revenues in both years attributable to R&D services provided to Amgen. The cost of revenues for quarter ended March 31, 2021 and 2020 were $58,000 and $42,000 respectively and were comprised of salaries and related expenses in connection with the R&D services provided to Amgen.

Operating expenses were $2.5 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020. Entera's operating loss was $2.4 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020.

Research and development expenses were $1.2 million for the quarter ended March 31, 2021, compared to $1.6 million for the quarter ended March 31, 2020. The decreasewas primarily due to a decrease of $0.2 million in professional and consulting services expenses due to submission of the IND in 2020 and a decrease of $0.2 million in EB613 clinical trial related expenses, including materials and production costs.

General and administrative expenses were $1.3 million for the quarter ended March 31, 2021, compared to $1.3 million for the quarter ended March 31, 2020. The quarter ended March 31, 2021 saw a decrease of $0.2 million in professional fees which was offset by an increase of $0.1 million in legal fees and $0.1 million in insurance and investor relations expenses.

Net comprehensive loss was $9.5 million or $0.43 per ordinary share (basic and diluted) for the quarter ended March 31, 2021 compared to $2.9 million, or $0.16 per ordinary share (basic and diluted) for the quarter ended March 31, 2020. The change in net loss was primarily due to the increase in the fair value of the warrants classified as financial liability, due to an increase in our market share price.

As of March 31, 2021, Entera had cash and cash equivalents of $16.4 million, compared to $8.6 million as of December 31, 2020. The increase was primarily due to sales under our ATM facility with Canaccord Genuity LLC.

Entera expects an operating loss of approximately $13.0 million for the year ending December 31, 2021 and believes its current cash position will be sufficient to fund its operations into the second quarter of 2022.

The Company's Board of Directors has decided to accelerate the termination date of its outstanding warrants, upon satisfaction of the sale price condition and in accordance with the terms of the warrants.

Conference Call and Webcast Information

Entera's management will host a conference call on Thursday, May 20, 2021 at 8:30 a.m. EDT. A question–and–answer session will follow Entera's remarks. To participate on the live call, please dial (855) 547–3865 (US) or (409) 217–8787 (international) and provide the conference ID "8483793" five to ten minutes before the start of the call.

To access a live audio webcast of the presentation on the "Investor Relations" page of Entera's website, please click here. A replay of the webcast will be archived on Entera's website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the complete 3–month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA's interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera's product candidates including EB612 and GLP–2; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera's Annual Report on Form 20–F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

Three months ended

March 31

2021


2020

U.S. dollars in thousands

REVENUE

157

42

COST OF REVENUE

58

42

RESEARCH AND DEVELOPMENT EXPENSES, net

1,159

1,605

GENERAL AND ADMINISTRATIVE EXPENSES

1,309

1,290

OTHER INCOME

10

OPERATING LOSS

2,359

2,895

FINANCIAL EXPENSES (INCOME):

Loss from change in fair value of financial liabilities at fair value

7,103

46

Other financial income, net

(12)

(23)

FINANCIAL EXPENSES, NET

7,091

23

LOSS BEFORE TAXES

9,450

2,918

TAXES ON INCOME

38

NET COMPREHENSIVE LOSS FOR THE PERIOD

9,488

2,918

U.S. dollars

LOSS PER ORDINARY SHARE –

Basic and Diluted

0.43

0.16

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING –

Basic and Diluted

21,890,100

18,048,827

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(US$ in thousands)

March 31

December 31

2021

2020

Unaudited

Cash and cash equivalents

16,381

8,593

Accounts receivable and other current assets

1,053

516

Other current assets

1,038

261

Property and equipment, net

182

192

Other assets, net

911

961

Total assets

18,527

10,262

Accounts payable and other current liabilities

2,081

1,841

Warrants liabilities

8,535

1,432

Total current liabilities

10,616

3,273

Total non–current liabilities

298

324

Total shareholders' equity

7,613

6,665

Total liabilities and shareholders' equity

18,527

10,262


GLOBENEWSWIRE (Distribution ID 8239692)

Nyxoah Reports Full Year 2020 Results

Nyxoah Reports Full Year 2020 Results

Conference call and webcast today at 3pm CET / 9am ET

Mont–Saint–Guibert, Belgium "" 9 April 2021 "" Nyxoah SA (Euronext Brussels: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the full year ended December 31, 2020.

Olivier Taelman, Chief Executive Officer of Nyxoah, said: "2020 was a year marked by key accomplishments for Nyxoah, with important milestones showing focused execution across business units. Despite the Covid–19 pandemic, the impact on Nyxoah's activities was limited and our manufacturing facilities remained operational, with sufficient production to meet our needs."

Key Points

  • Financial
    • 25M round onboarding ResMed as new investor
    • 85M IPO on Euronext Brussels
  • Clinical
    • BETTER SLEEP study enrolment close of 42 implanted patients M6 data to be expected Q2 2021
    • IDE trial approval by FDA in June 2020, with first US and international implants by end 2020
    • EliSA implants on 15 patients for long term safety & efficacy, trial expected to follow patients over a five–year period
  • Commercial
    • Germany G–BA approving NUB reimbursement at a similar reimbursement level as other neurostimulation–based OSA therapies
    • First revenue generation in Germany
  • Operational
    • No production stop despite COVID
    • Tech transfer to a second independent manufacturing site in Belgium started
  • R&D
    • MRI compatibility full body 1.5T and 3T
    • Next Gen of Genio system with improved features for the implantable and external components

Highlights of 2020

  • In 2020, the Company continued to advance its goal of further expanding its footprint and providing more patients suffering from OSA access to the Genio solution, thereby addressing a significant current unmet medical need.
  • The German federal joint committee (G–BA) confirmed in March 2020 that the Genio system is entitled to join the existing NUB for hypoglossal nerve stimulation ("HGNS") systems at a similar reimbursement level as other neurostimulation–based OSA therapies. As a result, the Company generated its first commercial revenue in 2020, albeit that such revenue was limited due to the NUB–specific negotiation path. As of 2021, the reimbursement will move away from NUB into a DRG system which should allow the Company to fully ramp up its German commercialization strategy.
  • Despite Covid–19 related disruptions, the Company was able to continue producing Genio devices in sufficient quantities to meet needs.

Clinical development

  • In November 2020, the Company completed enrolments in the BETTER SLEEP trial, conducted in Australia. In total, 42 patients were enrolled in this pre–marketing study, designed to assess the safety and efficacy / performance of the Genio system for the treatment of OSA in adult patients who either exhibit or do not exhibit a complete concentric collapse ("CCC") of the soft palate. The study is planned to have a 36–month follow–up and the end of the study is expected by the end of 2023. Six–month follow–up results are expected to be available in the second quarter of 2021.
  • If the primary endpoints of this study are reached, the Company plans to request a therapy indication expansion that would allow the Genio system to be used to treat CCC patients that are currently excluded from HGNS. In the meantime, the discussion with the European notified bodies has been initiated. If the Company obtains marketing authorization for the Genio system in the US, the Company plans to leverage the clinical data from the BETTER SLEEP study to expand the authorized indication to include the treatment of CCC patients in the US.
  • In 2020, enrolment continued, but was slowed down due to Covid–19, in the EliSA trial, the Company's multicenter post–marketing trial being conducted throughout Europe which is designed to gather long–term safety and clinical data regarding the Genio system in adult patients suffering from moderate–to–severe OSA. As of 31 December 2020, 15 patients out of the total intended 110 patients were enrolled in the study coming from five different countries (Germany, Switzerland, France, the Netherland, Belgium).
  • In June 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application for the Company's DREAM trial. This study aims to confirm the safety and effectiveness of the Genio system and is designed to support marketing authorization of the Genio system in the United States. The study will enroll 134 moderate–to–severe OSA patients who failed first line CPAP therapy. Up to 19 US sites in combination with 7 international sites have been selected to participate in the study. By the end of 2020, the first US and international implants took place.

Research and Development

  • Throughout 2020, the Company continued to invest in improving the Genio system with a goal of developing next generation products with improved features with respect to patient comfort, therapy efficacy, reliability and patient and market acceptance.
  • In 2020, the Company performed the Magnetic Resonance Imaging ("MRI") compatibility testing of the Genio system, resulting in CE mark and FDA conditional MR labeling approval in early 2021.

Financial highlights

  • In February 2020, the Company raised 25 million in a private financing round, whereby ResMed Inc. (NYSE:RMD; ASX:RMD), a world–leading digital health company in the OSA field, joined the Company as a new shareholder. All major shareholders at that time participated in this financing round onboarding ResMed Inc.
  • In September 2020, the Company raised 85 million ($100 million) as a result of the initial public offering ("IPO") of new shares of the Company on Euronext Brussels under the symbol "NYXH". The IPO resulted in an initial market capitalization of 375 million (taking into account the exercise in full of the over–allotment option in the framework of the IPO).

Subsequent Events

  • After the close of the financial year, the Company signed an exclusive license agreement with Vanderbilt University (Nashville, TN, USA). This agreement allows Nyxoah to develop new neurostimulation technologies for the treatment of sleep disordered breathing conditions based on inventions and patents owned by Vanderbilt University, which could potentially expand Nyxoah's future pipeline.
  • On February 22, 2021, the Company issued 10,000 shares pursuant to an exercise of subscription rights. Consequently, on the date of this Annual Report, the Company's registered capital amounts to EUR 3,797,765.64, represented by 22.107.609 shares.

Outlook for 2021

Our business, operational, and clinical outlook for 2021 include the following:

  • Ramp up EU revenue and build a dedicated sales team in Germany
  • Obtain reimbursement in Switzerland
  • BETTER SLEEP trial 6 month results, basis for Complete Concentric Collapse ("CCC") therapeutic indication expansion
  • Open second independent manufacturing site in Belgium, in addition to existing site in Israel
  • Complete DREAM pivotal trial enrollment

Full Year 2020 Financial Results
Income Statement

For the first time since its inception, the Company began generating revenue as of July 2020. The revenue of KEUR 69 was generated under the existing HGNS NUB coding in Germany. The total cost of goods sold was KEUR 30.

Operating costs increased to KEUR 11,224 in 2020 from KEUR 7,715 in 2019, or a change of KEUR 3,509, due to increases of activities in all departments. The Company is currently conducting three clinical trials to continue gathering clinical data and obtain regulatory approvals. In June 2020 the Company obtained FDA approval to start the DREAM study in the US. In line with its strategy, the Company continues investing in research and development to improve and develop the next generation of the Genio system and preparing for scaling–up of production capacities.

General and administrative expenses increased by 78% to KEUR 7,522 in 2020 from KEUR 4,226 in 2019. The increase is due to consulting expenses, staff and legal fees to support the Company growth. The increase in consulting and contractors' fees includes variable compensations of KEUR 1,981 related to a cash–settled share–based payment transaction (2019: KEUR 1,199). The increase of KEUR 159 in legal fees is due to services and not to any ongoing disputes.

Research and development expenses increased by 29% to KEUR 3,066 in 2020 from KEUR 2,375 in 2019, before capitalization of KEUR 2,593 in 2020, due to the increase of development costs of the Genio system. Research and development expenses consist of product development, engineering to develop and support our products, testing, consulting services and other costs associated with the next generation of the Genio system that do not meet the development capitalization criteria. The Company continues to invest in improving the Genio system to develop next generation products with improved features with respect to patient comfort, therapy efficacy, reliability and patient and market acceptance. These expenses primarily include employee compensation and outsourced development expenses.

Clinical expenses increased by 50% to KEUR 4,316 in 2020 from KEUR 2,881 in 2019, before capitalization of KEUR 3,263 in 2020. The increase in the expenses was mainly due to an increase in staff and consulting to support the completion of the BETTER SLEEP study implantations, continuous recruitment for EliSA study and the launch of the new DREAM IDE study in the US. Clinical expenses consist of clinical studies related to the development of our Genio system, consulting services and other costs associated with clinical activities. These expenses include employee compensation, clinical trial management and monitoring, payments to clinical investigators, data management and travel expenses for our various clinical trials.

Manufacturing expenses increased by 109% to KEUR 3,802 in 2020 from KEUR 1,812 in 2019, before capitalization of KEUR 3,342 in 2020. The increase in the expenses was mainly due to increases in staff for the production and engineering teams to support capacity and yield improvement, and also due to purchasing raw materials to support increase in the production. Manufacturing and operation expenses consist primarily of acquisition costs of the components of the Genio system, scrap and inventory obsolescence as well as distribution–related expenses such as logistics and shipping costs.

Quality assurance and regulatory expenses increased by 58% to KEUR 1,474 in 2020 from KEUR 928 in 2019, before capitalization of KEUR 1,247 in 2020. The increase in the expenses was due to staff increases and QA & regulatory activities to support manufacturing scaling up process. Quality assurance and regulatory expenses consist primarily of quality control, quality assurance and regulatory expenses. These expenses include employee compensation, consulting, testing and travel expenses.

Therapy development expenses increased by 107% to KEUR 1,864 in 2020 from KEUR 902 in 2019. The increase in the expenses was due to an increase in staff and consulting to support the commercialization in Europe. Therapy development expenses consist of compensation for personnel, spending related to market access and reimbursement activities. Other therapy development expenses include training physicians, travel expenses, conferences and consulting services.

Balance Sheet

The Company started recognizing the development expenditure as an asset as of March 2019, triggered by obtaining CE mark. Development costs primarily include employee compensation and outsourced development expenses. In 2020, the Company had capitalized developments costs of KEUR 9,874.

Property, plant & equipment shows a total additional net book value of KEUR 391 at balance sheet date consequently to leasehold improvements in the Company's offices in Belgium and Israel. Right of use assets shows a total additional increase by KEUR 2,217 due to new leases signed in 2020.

Cash and cash equivalents show a total additional increase of KEUR 86,445. This increase was due to total capital raises of KEUR 103,583, net of transaction costs, in February 2020 and in September 2020 (Initial Public Offering ("IPO")). Cash from financing activities was offset by cash used in the operating activities of KEUR 7,015 and cash used in the investing activities of KEUR 10,693.

The share capital and the share premium have increased, respectively, by KEUR 1,315 and KEUR 103,268 due to the capital increases in cash in 2020 for a total amount KEUR 103,583, net of transaction costs and capital increase in kind (conversion of loan in shares) of KEUR 1,000.

Lease liabilities shows a total additional increase of KEUR 2,242 due to new lease agreements in Belgium and Israel.

Other non–current and current payables have increased by KEUR 1,303 from KEUR 2,820 to KEUR 4,123 due higher cash–settled share–based payment liability of KEUR 473, higher accrued expenses of KEUR 557 and higher payroll related payables of KEUR 134.

Cash Flow Statement

The net cash burn rate for 2020 is a net cash inflow amounting to KEUR 86,445 compared to a net cash outflow of KEUR 10,950 for 2019.

The cash outflow resulting from operating activities amounted to KEUR 7,015 in 2020 compared to KEUR 5,965 in 2019. An increase of cash outflow of KEUR 1,050 due to KEUR 3,768 higher losses mainly from increased general and administrative expenses and therapy development expenses and higher interest and tax paid, net of KEUR 166, offset by KEUR 2,421 higher non–operating cash adjustments (KEUR 2,202 higher share–based payment expense) and a positive variation in the working capital of KEUR 463.

Cash flow from investing activities represented a net cash outflow of KEUR 10,693 for 2020. An increase of KEUR 4,898 compared to 2019 mainly explained by higher capitalization of development expenses in 2020.

The increase in cash inflow from financing activities is primarily due to the IPO completed in September 2020 and the proceeds from the February 2020 capital raise.

Financial Information

The consolidated financial statements have been prepared in accordance with IFRS as adopted by the EU. The financial information included in this press release is an extract of the full IFRS consolidated financial statements, which will be published on 9 April 2021. The statutory auditor, EY Bedrijfsrevisoren /Rviseurs d'Entreprises SRL, represented by Carlo–Sbastien D'Addario, has issued an unqualified audit opinion with emphasis of matter paragraph relating to a restatement for the year 2019 and the balance at 1 January 2019 to reflect the adjustments relating to a share based compensation accrual.

2021 Financial & Events Calendar

  • 09 April 2021 Full Year 2020 Financial and Operating Results & Annual Report
  • 09 June 2021 Annual Shareholders' Meeting
  • 31 August 2021 Interim Financial Report H1, 2021
  • 14–15 September 2021 Baird 2021 Global Healthcare Conference (virtual)

Conference Call & Webcast
Nyxoah will host a conference call with live webcast today at 3pm CET/9am ET. The webcast may be accessed on the Events page of the company's website or by clicking here. A replay of the webcast will be available on the Nyxoah website.

For further information, please contact:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
vivian.cervantes@gilmartinir.com

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal
law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other

factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such
forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Consolidated Income Statement

For the year ended 31 December
(in EUR 000) 2020 2019
Restated *
Revenue 69
Cost of goods sold (30)
Gross Profit 39
General and administrative expenses (7,522) (4,226)
Research and development expenses (473) (630)
Clinical expenses (1,053) (848)
Manufacturing expenses (460) (489)
Quality assurance and regulatory expenses (227) (227)
Patents Fees & Related (123) (267)
Therapy Development expenses (1,864) (902)
Other operating income/ (expenses) 459 (126)
Operating loss for the period (11,224) (7,715)
Financial income 62 71
Financial expense (990) (740)
Loss for the period before taxes (12,152) (8,384)
Taxes (93) (70)
Loss for the period (12,245) (8,454)
Loss attributable to equity holders1 (12,245) (8,454)
Other comprehensive (loss) / income
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences (58) 168
Total comprehensive loss for the year, net of tax (12,303) (8,286)
Loss attributable to equity holders1 (12,303) (8,286)
Basic Earnings Per Share (in EUR) (0.677) (0.568)
Diluted Earnings Per Share (in EUR) (0.677) (0.568)

Consolidated Statement of Financial Position

As of and for the year ended 31 December
(in EUR 000) 2020 2019
Restated*
ASSETS
Non–current assets
Property, plant and equipment 713 322
Intangible assets 15,853 5,734
Right of use assets 3,283 1,066
Deferred tax asset 32 21
Other long–term receivables 91 78
19,972 7,221
Current assets
Inventory 55
Trade receivables 60
Other receivables 1,644 2,048
Other current assets 109 11
Cash and cash equivalents 92,300 5,855
94,108 7,974
Total assets 114,080 15,195

EQUITY AND LIABILITIES

Capital and reserves
Capital 3,796 2,481
Share premium 150,936 47,668
Share based payment reserve 2,650 420
Currency translation reserve 149 207
Retained Earnings (60,341) (48,415)
Total equity attributable to shareholders 97,190 2,361
LIABILITIES
Non–current liabilities
Financial debt 7,607 7,146
Lease liability 2,844 735
Pension Liability 37 30
Other payables 547
10,488 8,458
Current liabilities
Financial debt 616 378
Lease liability 473 340
Trade payables 1,190 1,385
Other payables 4,123 2,273
6,402 4,376
Total liabilities 16,890 12,834
Total equity and liabilities 114,080 15,195

____________________________________

* The year 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note "5.2.3

Consolidated Statement of Cash Flows

For the year ended 31 December
(in EUR 000) 2020 2019
Restated *
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax for the year (12,152) (8,384)
Adjustments for:
Finance income (62) (71)
Finance expenses 990 740
Depreciation and impairment of property, plant
and equipment and right–of–use assets
620 433
Share–based payment transaction expense 2,549 346
Pension–related expenses 7 30
Other non–cash items2 (134) 70
Cash generated before changes in working capital (8,182) (6,836)
Changes in working capital:
Increase in Inventory (55)
Decrease/(Increase) in Trade and other receivables 365 (1,385)
Increase in Trade and other payables 1,109 2,342
Cash generated from changes in operations (6,763) (5,879)
Interests received 3 8
Interests paid (151) (33)
Income tax paid (104) (61)
Net cash used in operating activities (7,015) (5,965)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment (562) (51)
Capitalization of intangible assets (10,118) (5,734)
Increase of long–term deposits (13) (10)
Net cash used in investing activities (10,693) (5,795)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of principal portion of lease liabilities (479) (341)
Repayment of other loan (63) (82)
Recoverable cash advance received 190 1,196
Repayment of recoverable cash advance (55) (40)
Proceeds from convertible loan 1,000
Proceeds from issuance of shares, net of transaction costs 103,583
Net cash generated/(used) from financing activities 104,176 733
Movement in cash and cash equivalents 86,468 (11,027)
Effect of exchange rates on cash and cash equivalents (23) 77
Cash and cash equivalents at 1 January 5,855 16,805
Cash and cash equivalents at 31 December 92,300 5,855

Consolidated Statement of Changes in Equity

Attributable to owners of the parent
(in EUR 000)

Notes

Capital Share premium Share based payment reserve Currency translation reserve Retained earnings Total
Balance at 1 January 2019* restated " 2,481 47,668 80 39 (39,967) 10,301
Loss for the year (8,454) (8,454)
Other comprehensive income for the year 168 168
Total comprehensive income/(loss) for the year 168 (8,454) (8,286)
Equity–settled share–based payment plan 340 6 346
Total transactions with owners of the Company recognized directly in equity 340 6 346
Balance at 31 December 2019 restated * 2,481 47,668 420 207 (48,415) 2,361
Balance at 1 January 2020 restated * 2,481 47,668 420 207 (48,415) 2,361
Loss for the year (12,245) (12,245)
Other comprehensive loss for the year (58) (58)
Total comprehensive loss for the year (58) (12,245) (12,303)
Equity–settled share–based payment plan 2,230 319 2,549
Issuance of shares for cash 1,304 108,857 110,161
Issuance of shares in kind 11 989 1,000
Transaction cost (6,578) (6,578)
Total transactions with owners of the Company recognized directly in equity 1,315 103,268 2,230 319 107,132
Balance at 31 December 2020 3,796 150,936 2,650 149 (60,341) 97,190

____________________________________

* The year 2019 and the balance at 1 January 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note "5.2.3


1 For the years ending 31 December 2020 and 2019, the loss is fully attributable to equity holders of the Company as the Company does not have any non–controlling interests.
* The year 2019 has been restated to reflect the adjustments as explained in Note "5.2.3

2 The other non–cash items include (i) the impact of the initial measurement and re–measurement of recoverable cash advances (see our 2020 Annual Report notes "5.14 ,"5.24 and (ii) the evolution of the deferred tax assets.
* The year 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note "5.2.3

Attachment


GLOBENEWSWIRE (Distribution ID 1000477389)

Bombardier Reports Full Year 2020 Financial Results, Provides 2021 Guidance and Outlines Actions to Drive Profitability and Productivity

  • 2020 revenues from Business Aircraft activities reached $5.6 billion, growing 3% year–over–year on 114 deliveries, 44 of which were in the fourth quarter, including a record 16 Global 7500 aircraft deliveries
  • 2020 adjusted EBITDA(1) of $200 million from continuing operations; $912 million of reported EBIT, reflects the accounting gains on disposal of the CRJ and aerostructures businesses
  • Fourth Quarter Free Cash Flow(1) (FCF) generation of $523 million from continuing operations before interest and taxes, ahead of plan; cash flow from operating activities of $323 million for the fourth quarter
  • Pro forma cash and cash equivalents(2) of $5.4 billion, including Cash on hand of $1.8 billion at Bombardier Inc. on December 31, 2020 and $3.6 billion of proceeds from the recently closed sale of Transportation once it becomes fully available; Pro–forma net debt(3) of approximately $4.7 billion
  • Company–wide initiative to drive profitability and productivity underway; Targeting savings of approximately $400 million(4) annually by 2023
  • Learjet production to end in Q4 2021, allowing the Company to focus on more profitable Challenger and Global aircraft families; Wichita to become Centre of Excellence for specialized aircraft platforms
  • 2021 outlook(4): Revenues expected to grow organically; Adjusted EBITDA and EBIT(1) expected to increase to greater than $500 million and $100 million respectively, and FCF usage expected to be better than $500 million, including one–time costs and investments
  • Company to host an Investor Day on March 4, 2021

All amounts in this press release are in U.S. dollars, unless otherwise indicated.
Amounts in tables are in millions except per share amounts, unless otherwise indicated.

MONTRÉAL, Feb. 11, 2021 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) today reported its fourth quarter and full year 2020 results, provided guidance for 2021 and outlined a number of actions to drive profitability and productivity as the Company focuses exclusively on designing, building and servicing the world's best business jets.

"With our strategic repositioning now complete, we are very excited to embark on our journey as a pure–play business jet company," said ric Martel, President and Chief Executive Officer, Bombardier Inc. "Our unmatched product portfolio, world–class customer services network, and incredibly talented employees give us a strong foundation to build upon. We are encouraged by our momentum in the fourth quarter and are confident in the actions we are taking to navigate through the pandemic and better position the Company for a market recovery."

Overview 2020 Financial Performance

Revenues from Business Aircraft activities reached $5.6 billion in 2020, reflecting a 3% year–over–year improvement, driven by the ramp up in Global 7500 deliveries, which reached a record 16 deliveries in the fourth quarter, partially offset by the significant impact of COVID–19 on other programs and services revenues.

Adjusted full year EBITDA and adjusted EBIT(1) for continuing operations of $200 million and $(211) million, respectively, reflect the impact of the COVID–19 pandemic on deliveries and services, as well as a lower contribution of early Global 7500 units. Reported EBIT of $0.9 billion reflects the accounting gains on disposals of the CRJ and aerostructures businesses.

Fourth quarter free cash flow generation from continuing operations before interest and taxes was $523 million. This was better than expected and notwithstanding a $160 million negative impact made in the quarter due to the winding down of the Company's reverse factoring program. Full year free cash flow usage from continuing operations was $1.9 billion, reflecting pandemic–related disruptions, and including corporate and interest expenses, which will be lower in 2021 given the expected debt paydown and restructuring actions announced today.

Bombardier begins 2021 with pro forma cash and cash equivalents of approximately $5.4 billion, including the proceeds from the recently closed sale of Transportation and a pro forma net debt of approximately $4.7 billion.

Driving Profitability and Productivity

Bombardier has and will be launching a number of actions to improve profitability and cash generation. The goal is to make the organization more efficient and agile, capable of delivering stronger financial performance under the current market conditions, while also establishing a lower cost base to grow from, once the market recovers. With these actions, the Company aims to generate $400 million annually in recurring savings by 2023. Savings are expected to be approximately $100 million in 2021; the Company will take a one–time charge of $50 million this year to support its restructuring actions.

Specific actions include consolidating Bombardier's Global aircraft completion work in Montral; reviewing options for underutilized hangar and industrial space at our Qubec facilities; and reducing its overall workforce by approximately 1,600 positions, including reductions associated with progress on the Global 7500 learning curve. These reductions, together with the completion of previously announced restructuring actions and the divestiture of the electrical wiring interconnection system business in Quertaro, Mexico, should bring the Corporation's global workforce to about 13,000 by year–end.

"Workforce reductions are always very difficult, and we regret seeing talented and dedicated employees leave the company for any reason," said Martel. "But these reductions are absolutely necessary for us to rebuild our company while we continue to navigate through the pandemic."

Bombardier also announced it will end production of Learjet aircraft later this year, allowing the Company to focus on its more profitable Challenger and Global aircraft families and accelerate the expansion of its customer services business.

"With more than 3,000 aircraft delivered since its entry–into–service in 1963, the iconic Learjet aircraft has had a remarkable and lasting impact on business aviation. Passengers all over the world love to fly this exceptional aircraft and count on its unmatched performance and reliability. However, given the increasingly challenging market dynamics, we have made this difficult decision to end Learjet production," explained Martel.

Bombardier will continue to fully support the Learjet fleet well into the future, and to this end, today launched the Learjet RACER remanufacturing program for Learjet 40 and Learjet 45 aircraft. RACER program includes a bundled set of enhancements, including interior and exterior components, new avionics, high–speed connectivity, engine enhancements, and improved aircraft maintenance costs. The RACER remanufacturing program will be offered exclusively through Bombardier's service centre in Wichita, Kansas.

Bombardier's Wichita facility will continue to serve as the Company's primary flight–test centre and be a key part of its global services network. In addition, Bombardier has designated Wichita as the Centre of Excellence for its specialized aircraft business and expects the facility will play a leading role in future special mission modification contracts.

2021 Guidance

With Bombardier's repositioning to a pure–play business aviation company now complete, 2021 will be a transition year as the Company executes its productivity actions, further matures Global 7500 production and begins to address its capital structure.

Revenues from business aircraft activities in 2021 are expected to be better than 2020 based on a gradual economic recovery scenario.

Adjusted EBITDA is expected to increase to greater than $500 million, reflecting ongoing progress on the Global 7500 learning curve, growth in customer services and the partial impact of the cost reduction actions. Adjusted EBIT is expected to be greater than $100 million.

Free cash flow usage in 2021 is expected to be better than $500 million, including one–time outflows related to the closing of the reverse factoring program; residual value guarantees; and the previously mentioned restructuring charge, which collectively are estimated to be approximately $200 million.

Investor Day

Bombardier will host a virtual Investor Day on March 4, 2021, during which the Leadership team will provide updates on its market outlook, debt management strategy and cost reduction actions. Details will be provided in a separate media advisory and posted on the company's website www.ir.bombardier.com at a later date in the near future.

Selected results

RESULTS
For the fiscal years ended December 31 2020 2019 Variance
restated
(5)
Revenues (6) $ 6,487 $ 7,488 (13 ) %
Adjusted EBITDA $ 200 $ 684 (71 ) %
Adjusted EBITDA margin 3.1 % 9.1 % (600) bps
Adjusted EBIT $ (211 ) $ 400 nmf
Adjusted EBIT margin (3.3 ) % 5.3 % (860) bps
EBIT $ 912 $ (520 ) nmf
EBIT margin 14.1 % (6.9 ) % 2100 bps
Net loss from continuing operations $ (170 ) $ (1,541 ) 89 %
Net loss from discontinued operations $ (398 ) $ (66 ) (503 ) %
Net loss $ (568 ) $ (1,607 ) 65 %
Diluted EPS from continuing operations (in dollars) $ (0.08 ) $ (0.65 ) $ 0.57
Diluted EPS from discontinued operations (in dollars) $ (0.29 ) $ (0.11 ) $ (0.18 )
$ (0.37 ) $ (0.76 ) $ 0.39
Adjusted net loss $ (1,115 ) $ (406 ) (175 ) %
Adjusted EPS (in dollars) $ (0.47 ) $ (0.18 ) $ (0.29 )
Cash flows from operating activities
Continuing operations $ (1,672 ) $ (253 ) (561 ) %
Discontinued operations $ (1,149 ) $ (427 ) (169 ) %
$ (2,821 ) $ (680 ) (315 ) %
Net additions to PP&E and intangible assets
Continuing operations $ 221 $ 366 (40 ) %
Discontinued operations $ 133 $ 157 (15 ) %
$ 354 $ 523 (32 ) %
Free cash flow usage
Continuing operations $ (1,893 ) $ (619 ) (206 ) %
Discontinued operations $ (1,282 ) $ (584 ) (120 ) %
$ (3,175 ) $ (1,203 ) (164 ) %
As at December 31 2020 2019 Variance
Cash and cash equivalents excluding Transportation $ 1,779 $ 2,089 (15 ) %
Cash and cash equivalents from Transportation $ 671 $ 540 24 %
$ 2,450 $ 2,629 (7 ) %
Available short–term capital resources(7) $ 3,203 $ 3,925 (18 ) %
Aviation order backlog (in billions of dollars)
Business aircraft $ 10.7 $ 14.4 (26 ) %
Other aviation(8) $ "" $ 1.9 (100 ) %
RESULTS
Fourth quarters ended
December 31
Fiscal years ended
December 31

2020
2019 2020
2019
restated
restated
Revenues $ 2,337 $ 2,412 $ 6,487 $ 7,488
Cost of sales 2,248 2,109 5,971 6,447
Gross margin 89 303 516 1,041
SG&A 117 126 420 557
R&D 144 65 320 156
Share of income of joint ventures and associates "" (56 ) (2 ) (34 )
Other income (7 ) "" (11 ) (38 )
Adjusted EBIT (165 ) 168 (211 ) 400
Special items (598 ) 1,628 (1,123 ) 920
EBIT 433 (1,460 ) 912 (520 )
Financing expense 240 236 1,060 996
Financing income (28 ) (93 ) (27 ) (226 )
EBT 221 (1,603 ) (121 ) (1,290 )
Income taxes 236 (75 ) 49 251
Net loss from continuing operations $ (15 ) $ (1,528 ) $ (170 ) $ (1,541 )
Net loss from discontinued operations $ (322 ) $ (191 ) $ (398 ) $ (66 )
Net loss $ (337 ) $ (1,719 ) $ (568 ) $ (1,607 )
Attributable to
Equity holders of Bombardier Inc. $ (423 ) $ (1,770 ) $ (868 ) $ (1,797 )
NCI $ 86 $ 51 $ 300 $ 190
EPS (in dollars)
Basic and diluted $ (0.18 ) $ (0.74 ) $ (0.37 ) $ (0.76 )
EPS from continuing operations (in dollars)
Basic and diluted $ (0.01 ) $ (0.64 ) $ (0.08 ) $ (0.65 )
As a percentage of total revenues
Gross margin 3.8 % 12.6 % 8.0 % 13.9 %
Adjusted EBIT (7.1 ) % 7.0 % (3.3 ) % 5.3 %
EBIT 18.5 % (60.5 ) % 14.1 % (6.9 ) %


SEGMENTED RESULTS AND HIGHLIGHTS

Aviation

RESULTS
For the fiscal years ended December 31 2020 2019 Variance
Revenues
Business aircraft 5,593 5,417 3 %
Other aviation 895 2,084 (57 ) %
Total Revenues 6,488 7,501 (14 ) %
Aircraft deliveries (in units)
Business aircraft 114 142 (28 )
Commercial aircraft (9) 5 33 (28 )
Adjusted EBITDA $ 286 $ 812 (65 ) %
Adjusted EBITDA margin 4.4 % 10.8 % (640) bps
Adjusted EBIT $ (125 ) $ 531 (124 ) %
Adjusted EBIT margin (1.9 ) % 7.1 % (900) bps
EBIT $ 937 $ 1,194 (22 ) %
EBIT margin 14.4 % 15.9 % (150) bps
Net additions to PP&E and intangible assets $ 221 $ 373 (41 ) %
As at December 31 2020
2019 Variance
Order backlog (in billions of dollars)
Business aircraft $ 10.7 $ 14.4 (26 ) %
Other aviation $ "" $ 1.9 (100 ) %
  • Revenues from Business Aircraft activities reached $5.6 billion in 2020, growing 3% year–over–year driven by the continued ramp up of Global 7500 aircraft deliveries, notwithstanding production rate adjustments on other platforms to align with market conditions and customer requirements in response to the COVID–19 pandemic.
    • Business aircraft manufacturing revenues increased 11% year–over–year, driven by the Global 7500 market shares gains in the extra long–range segment.
    • Services revenues were $988 million, 21% lower year–over–year, as the COVID–19 pandemic drove business jet utilization across the industry lower. The Corporation continues to position itself to capture future growth opportunities in aftermarket services by adding significant new capacity to its global network with major expansion projects underway in Singapore, London, Melbourne and Miami.
  • Business aircraft delivered 114 aircraft including specialized aircraft during the year, comprised of 59 Global, 44 Challenger, and 11 Learjet.
    • Deliveries peaked during the fourth quarter with 44 aircraft delivered, including a record 16 Global 7500 deliveries.
  • Other aviation revenues from commercial aircraft and aerostructures activities, which were divested during the course of the year, were $895 million.
  • Adjusted EBITDA and adjusted EBIT of 4.4% and (1.9)%, respectively, reflect lower aircraft deliveries and services activities, and low contribution of early Global 7500 units as the program continues to progress on its production learning curve, combined with the impact of reshaping a commercial agreement. Reported EBIT of $0.9 billion reflects the accounting gains on disposals of the CRJ and aerostructures businesses.
  • Business aircraft's multi–year backlog totalled $10.7 billion at the end of the year, reflecting higher order activity in the fourth quarter, net of reshaping a commercial agreement reclaiming 12 Global 7500 positions.
    • In December, Bombardier announced a firm order for 10 Challenger 350 aircraft in a transaction valued at $267 million, based on 2020 list prices. The firm commitment from an undisclosed customer represents one of the largest business jet orders of 2020 and underscores the desirability of best–selling Challenger 350 aircraft amid strong interest in business aviation and the enhanced safety it provides.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier, Challenger, Challenger 350, Global, Global 7500, Learjet, Learjet 40 and Learjet 45 are trademarks of Bombardier Inc. or its subsidiaries.

For information

Jessica McDonald
Advisor, Media Relations and Public Affairs
Bombardier Inc.
+1 514 861 9481
Patrick Ghoche
Vice President, Investor Relations
Bombardier Inc.
+1 514 861 5727

Readers are strongly advised to view a more detailed discussion of our results by segment in our Management's Discussion and Analysis and Consolidated financial statements which are posted on our website at ir.bombardier.com.

bps: basis points
nmf: information not meaningful

(1) Non–GAAP financial measures. Refer to the Non–GAAP financial measures and Liquidity and capital resources sections in the MD&A of the Corporation's financial report for the fiscal year ended December 31, 2020 for definitions of these metrics and the Analysis of results section thereafter for reconciliations to the most comparable IFRS measures.
(2) Non–GAAP financial measure. Pro–forma cash and cash equivalents includes cash and cash equivalents at Bombardier Inc. (excluding Transportation) of $1.8 billion as of December 31, 2020 and net proceeds of approximately $3.6 billion from the sale of Bombardier Transportation, which assumes the full monetization of Alstom shares worth approximately $600 million, the release of any cash not immediately available and is before the deployment of proceeds against any debt payment.
(3) Non–GAAP financial measure. Pro–forma net debt is defined as Long–term debt of $10.1 billion less cash and cash equivalents at Bombardier Inc. (excluding Transportation) of $1.8 billion as of December 31, 2020 less net proceeds of approximately $3.6 billion from the sale of Bombardier Transportation, which includes approximately $600 million of Alstom shares.
(4) See the forward–looking statements disclaimer at the end of this press release as well as the guidance and forward–looking statements section in the Overview section in the MD&A of the Corporation's financial report for the fiscal year ended December 31, 2020, for details regarding the assumptions on which the forward–looking statements are based.
(5) Transportation was classified as discontinued operations as of December 31, 2020. As a result, the results of operations have been restated for comparative periods. Refer to Note 31 – Discontinued operations to our Consolidated financial statements for more details.
(6) Includes continuing operations only.
(7) Defined as cash and cash equivalents including cash and cash equivalents from Transportation plus the undrawn amounts under Transportation's revolving credit facility and our senior secured term loan.
(8) Included the firm orders amounting to $1.1 billion from the aerostructures businesses presented under Assets held for sale as of December 31, 2019. Also included 20 firm orders for CRJ900 as of December 31, 2019. The backlog for the CRJ Series aircraft program amounting to $0.4 billion was removed as a result of the closing of the sale of the CRJ Series aircraft program to MHI on June 1, 2020.
(9) On May 31, 2019, the Corporation completed the sale of the Q Series aircraft program assets, including aftermarket operations and assets, to De Havilland Aircraft of Canada Limited (formerly Longview Aircraft Company of Canada Limited). On June 1, 2020, the Corporation completed the sale of the regional jet program to Mitsubishi Heavy Industries, Ltd. (MHI).

CAUTION REGARDING NON–GAAP MEASURES
This press release is based on reported earnings in accordance with IFRS and on the following non–GAAP financial measures:

Non–GAAP financial measures
Adjusted EBIT EBIT excluding special items. Special items comprise items which do not reflect the Corporation's core performance or where their separate presentation will assist users of the consolidated financial statements in understanding the Corporation's results for the period. Such items include, among others, the impact of restructuring charges, impact of business disposals and significant impairment charges and reversals.
Adjusted EBITDA Adjusted EBIT plus amortization and impairment charges on PP&E and intangible assets.
Adjusted net income (loss) Net income (loss) excluding special items, accretion on net retirement benefit obligations, certain net gains and losses arising from changes in measurement of provisions and of financial instruments carried at FVTP&L and the related tax impacts of these items.
Adjusted EPS EPS calculated based on adjusted net income attributable to equity holders of Bombardier Inc., using the treasury stock method, giving effect to the exercise of all dilutive elements.
Free cash flow (usage) Cash flows from operating activities less net additions to PP&E and intangible assets.

Non–GAAP financial measures are mainly derived from the consolidated financial statements but do not have standardized meanings prescribed by IFRS. The exclusion of certain items from non–GAAP performance measures does not imply that these items are necessarily non–recurring. Other entities in our industry may define the above measures differently than we do. In those cases, it may be difficult to compare the performance of those entities to ours based on these similarly–named non–GAAP measures.

Adjusted EBIT, adjusted EBITDA, adjusted net income (loss) and adjusted EPS
Management uses adjusted EBIT, adjusted EBITDA, adjusted net income (loss) and adjusted EPS for purposes of evaluating underlying business performance. Management believes these non–GAAP earnings measures in addition to IFRS measures provide users of our Financial Report with enhanced understanding of our results and related trends and increases the transparency and clarity of the core results of our business. Adjusted EBIT, adjusted EBITDA, adjusted net income (loss) and adjusted EPS exclude items that do not reflect our core performance or where their exclusion will assist users in understanding our results for the period. For these reasons, a significant number of users of the MD&A analyze our results based on these financial measures. Management believes these measures help users of MD&A to better analyze results, enabling better comparability of our results from one period to another and with peers.

Free cash flow (usage)
Free cash flow is defined as cash flows from operating activities less net additions to PP&E and intangible assets. Management believes that this non–GAAP cash flow measure provides investors with an important perspective on the Corporation's generation of cash available for shareholders, debt repayment, and acquisitions after making the capital investments required to support ongoing business operations and long–term value creation. This non–GAAP cash flow measure does not represent the residual cash flow available for discretionary expenditures as it excludes certain mandatory expenditures such as repayment of maturing debt. Management uses free cash flow as a measure to assess both business performance and overall liquidity generation.

Reconciliations of non–GAAP financial measures to the most comparable IFRS financial measures are provided in the tables hereafter, except for the following reconciliations:

  • adjusted EBIT to EBIT "" see the Results of operations tables in the reporting segments and Consolidated results of operations section; and
  • free cash flow usage to cash flows from operating activities "" see and the tables below and the Free cash flow usage table in the Liquidity and capital resources section.
Reconciliation of segment to consolidated results
Fourth quarters ended
December 31

Fiscal years ended
December 31

2020
2019 (1) 2020
2019 (1)
Revenues
Aviation $ 2,337 $ 2,413 $ 6,488 $ 7,501
Transportation(1) 2,076 1,793 7,844 8,269
Corporate and Others "" (1 ) (1 ) (13 )
$ 4,413 $ 4,205 $ 14,331 $ 15,757
Reclassification(1) (2,076 ) (1,793 ) (7,844 ) (8,269 )
$ 2,337 $ 2,412 $ 6,487 $ 7,488
Adjusted EBIT(2)
Aviation $ (149 ) $ 143 $ (125 ) $ 531
Transportation(1) (340 ) (234 ) (610 ) 70
Corporate and Others(3) (16 ) 25 (86 ) (131 )
$ (505 ) $ (66 ) $ (821 ) $ 470
Reclassification(1) 340 234 610 (70 )
$ (165 ) $ 168 $ (211 ) $ 400
Special Items
Aviation $ (628 ) $ 49 $ (1,062 ) $ (663 )
Transportation(1) (4 ) 2 8 48
Corporate and Others 30 1,579 (61 ) 1,583
$ (602 ) $ 1,630 $ (1,115 ) $ 968
Reclassification(1) 4 (2 ) (8 ) (48 )
$ (598 ) $ 1,628 $ (1,123 ) $ 920
EBIT
Aviation $ 479 $ 94 $ 937 $ 1,194
Transportation(1) (336 ) (236 ) (618 ) 22
Corporate and Others(3) (46 ) (1,554 ) (25 ) (1,714 )
$ 97 $ (1,696 ) $ 294 $ (498 )
Reclassification(1) 336 236 618 (22 )
$ 433 $ (1,460 ) $ 912 $ (520 )

Reconciliation of adjusted EBITDA to EBIT (4)
Fourth quarters
ended December 31
Fiscal years
ended December 31
2020 2019 2020 2019
EBIT $ 433 $ (1,460 ) $ 912 $ (520 )
Amortization 164 91 411 283
Impairment charges on PP&E and intangible assets(5) 17 "" 42 1
Special items excluding impairment charges on PP&E and intangible assets(5) (615 ) 1,628 (1,165 ) 920
Adjusted EBITDA $ (1 ) $ 259 $ 200 $ 684

(1) Transportation was classified as discontinued operations as of December 31, 2020. As a result, the results of operations have been restated for comparative periods. Refer to Note 31 – Discontinued operations to our Consolidated financial statements for more details.
(2) Non–GAAP financial measure. Refer to the Non–GAAP financial measures section for a definition of this metric.
(3) Includes share of income from ACLP of $3 million for fiscal year ended December 31, 2020. ($57 million and $37 million for the fourth quarter and fiscal year ended December 31, 2019, respectively. The share of net gains from ACLP in the fourth quarter of 2019 includes certain provision reversals within ACLP amounting to approximately $60 million.) On February 12, 2020, Bombardier transferred its remaining interest in ACLP to Airbus and the Government of Qubec.
(4) Includes continuing operations only.
(5) Refer to the Consolidated results of operations section for details regarding special items.

Reconciliation of adjusted net income (loss) to net loss and computation of adjusted EPS(1)
Fourth quarters ended December 31
2020
2019
(per share)
(per share)
Net loss from continuing operations $ (15 ) $ (1,528 )
Adjustments to EBIT related to special items(2) (598 ) $ (0.25 ) 1,628 $ 0.68
Adjustments to net financing expense related to:
Accretion on net retirement benefit obligations 13 0.01 17 $ ""
Net change in provisions arising from changes in interest rates and net loss on certain financial instruments (24 ) (0.01 ) (78 ) (0.03 )
Tax impact of special(2) and other adjusting items 149 0.06 (28 ) (0.01 )
Adjusted net income (loss) (475 ) 11
Preferred share dividends, including taxes 1 (7 )
Adjusted net income (loss) attributable to equity holders of Bombardier Inc. $ (474 ) $ 4
Weighted–average adjusted diluted number of common shares (in thousands) 2,419,541 2,397,868
Adjusted EPS $ (0.20 ) $ 0.00

Reconciliation of adjusted EPS to diluted EPS (in dollars) (1)
Fourth quarters ended December 31
2020
2019
Diluted EPS from continuing operations $ (0.01 ) $ (0.64 )
Impact of special(2) and other adjusting items (0.19 ) 0.64
Adjusted EPS $ (0.20 ) $ 0.00

Reconciliation of adjusted net loss to net loss and computation of adjusted EPS(1)
Fiscal years ended December 31
2020
2019
(per share)
(per share)
Net loss from continuing operations $ (170 ) $ (1,541 )
Adjustments to EBIT related to special items(2) (1,123 ) $ (0.47 ) 920 $ 0.39
Adjustments to net financing expense related to:
Loss on repurchase of long–term debt(2) "" "" 84 0.03
Accretion on net retirement benefit obligations 52 0.02 56 0.02
Net change in provisions arising from changes in interest rates and net loss (gain) on certain financial instruments 159 0.07 (140 ) (0.06 )
Tax impact of special(2) and other adjusting items (33 ) (0.01 ) 215 0.09
Adjusted net loss (1,115 ) (406 )
Preferred share dividends, including taxes (18 ) (21 )
Adjusted net loss attributable to equity holders of Bombardier Inc. $ (1,133 ) $ (427 )
Weighted–average adjusted diluted number of common shares (in thousands) 2,408,209 2,383,987
Adjusted EPS $ (0.47 ) $ (0.18 )

Reconciliation of adjusted EPS to diluted EPS (in dollars)(1)
Fiscal years ended December 31
2020
2019
Diluted EPS from continuing operations $ (0.08 ) $ (0.65 )
Impact of special(2) and other adjusting items (0.39 ) 0.47
Adjusted EPS $ (0.47 ) $ (0.18 )

(1) Includes continuing operations only.
(2) Refer to the Consolidated results of operations section for details regarding special items.

Reconciliation of free cash flow (usage) (1) to cash flows from operating activities
Fourth quarters
ended December 31
Fiscal years
ended December 31
2020 2019 2020 2019
Cash flows from operating activities 323 1,073 $ (2,821 ) $ (680 )
Net additions to PP&E and intangible assets (114 ) (121 ) (354 ) (523 )
Free cash flow (usage) (1) $ 209 $ 952 $ (3,175 ) $ (1,203 )

(1) Non–GAAP financial measure. Refer to the Non–GAAP financial measures section for a definition of this metric.

FORWARD–LOOKING STATEMENTS

This press release includes forward–looking statements, which may involve, but are not limited to: statements with respect to our objectives, anticipations and outlook or guidance in respect of various financial and global metrics and sources of contribution thereto, targets, goals, priorities, market and strategies, financial position, financial performance, market position, capabilities, competitive strengths, credit ratings, beliefs, prospects, plans, expectations, anticipations, estimates and intentions; general economic and business outlook, prospects and trends of an industry; customer value; expected demand for products and services; growth strategy; product development, including projected design, characteristics, capacity or performance; expected or scheduled entry–into–service of products and services, orders, deliveries, testing, lead times, certifications and execution of orders in general; competitive position; expectations regarding revenue and backlog mix; the expected impact of the legislative and regulatory environment and legal proceedings; strength of capital profile and balance sheet, creditworthiness, available liquidities and capital resources, expected financial requirements, and ongoing review of strategic and financial alternatives; the introduction of, productivity enhancements, operational efficiencies, cost reduction and restructuring initiatives, and anticipated costs, intended benefits and timing thereof; the anticipated business transition to growth cycle and cash generation; expectations, objectives and strategies regarding debt repayment, refinancing of maturities and interest cost reduction; expectations regarding availability of government assistance programs, compliance with restrictive debt covenants; expectations regarding the declaration and payment of dividends on our preferred shares; intentions and objectives for our programs, assets and operations; and the impact of the COVID–19 pandemic on the foregoing and the effectiveness of plans and measures we have implemented in response thereto; and expectations regarding gradual market and economic recovery in the aftermath of the COVID–19 pandemic. As it relates to the sale of the Transportation business to Alstom, this press release also contains forward–looking statements with respect to the benefits of such transaction, the use of the proceeds derived from the transaction and its impact on our outlook, guidance and targets, operations, infrastructure, opportunities, financial condition, business plan and overall strategy.

Forward–looking statements can generally be identified by the use of forward–looking terminology such as "may", "will", "shall", "can", "expect", "estimate", "intend", "anticipate", "plan", "foresee", "believe", "continue", "maintain" or "align", the negative of these terms, variations of them or similar terminology. Forward–looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of our current objectives, strategic priorities, expectations, outlook and plans, and in obtaining a better understanding of our business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

By their nature, forward–looking statements require management to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecast results set forth in forward–looking statements. While management considers these assumptions to be reasonable and appropriate based on information currently available, there is risk that they may not be accurate. The assumptions underlying the forward–looking statements made in this press release in relation to the sale of the Transportation business to Alstom discussed herein include the following material assumptions: the realization of the intended benefits from this transaction and the deployment of proceeds towards debt pay down. For additional information, including with respect to other assumptions underlying the forward–looking statements made in this press release, refer to the Guidance and Forward–looking Statements section in the MD&A of our financial report for the fiscal year ended December 31, 2020. Given the impact of the changing circumstances surrounding the COVID–19 pandemic and the related response from the Corporation, governments (federal, provincial and municipal), regulatory authorities, businesses, suppliers, customers, counterparties and third–party service providers, there is inherently more uncertainty associated with the Corporation's assumptions as compared to prior years.

Certain factors that could cause actual results to differ materially from those anticipated in the forward–looking statements include, but are not limited to, risks associated with general economic conditions, risks associated with our business environment (such as risks associated with the financial condition of business aircraft customers; trade policy; increased competition; political instability and force majeure events or global climate change), operational risks (such as risks related to developing new products and services; development of new business ; order backlog; the transition to a pure–play business aviation company; the certification of products and services; the execution of orders; pressures on cash flows and capital expenditures based on seasonality and cyclicality; execution of our strategy, productivity enhancements, operational efficiencies, restructuring and cost reduction initiatives; doing business with partners; product performance warranty and casualty claim losses; regulatory and legal proceedings; environmental, health and safety risks; dependence on certain customers, contracts and suppliers; supply chain risks; human resources; reliance on information systems; reliance on and protection of intellectual property rights; reputation risks; risk management; tax matters; and adequacy of insurance coverage), financing risks (such as risks related to liquidity and access to capital markets; retirement benefit plan risk; exposure to credit risk; substantial debt and interest payment requirements; restrictive debt covenants; reliance on debt management and interest cost reduction strategies; and reliance on government support), market risks (such as foreign currency fluctuations; changing interest rates; increases in commodity prices; and inflation rate fluctuations). For more details, see the Risks and uncertainties section in Other in the MD&A of our financial report for the fiscal year ended December 31, 2020. Any one or more of the foregoing factors may be exacerbated by the ongoing COVID–19 outbreak and may have a significantly more severe impact on the Corporation's business, results of operations and financial condition than in the absence of such outbreak. As a result of the current COVID–19 pandemic, additional factors that could cause actual results to differ materially from those anticipated in the forward–looking statements include, but are not limited to: risks related to the impact and effects of the COVID–19 pandemic on economic conditions and financial markets and the resulting impact on our business, operations, capital resources, liquidity, financial condition, margins, prospects and results; uncertainty regarding the magnitude and length of economic disruption as a result of the COVID–19 outbreak and the resulting effects on the demand environment for our products and services; uncertainty regarding market and economic recovery in the aftermath of the COVID–19 pandemic; emergency measures and restrictions imposed by public health authorities or governments, fiscal and monetary policy responses by governments and financial institutions; disruptions to global supply chain, customers, workforce, counterparties and third–party service providers; further disruptions to operations, orders and deliveries; technology, privacy, cyber security and reputational risks; and other unforeseen adverse events.

Readers are cautioned that the foregoing list of factors that may affect future growth, results and performance is not exhaustive and undue reliance should not be placed on forward–looking statements. Other risks and uncertainties not presently known to us or that we presently believe are not material could also cause actual results or events to differ materially from those expressed or implied in our forward–looking statements. The forward–looking statements set forth herein reflect management's expectations as at the date of this report and are subject to change after such date. Unless otherwise required by applicable securities laws, we expressly disclaim any intention, and assume no obligation to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise. The forward–looking statements contained in this press release are expressly qualified by this cautionary statement.


GLOBENEWSWIRE (Distribution ID 8151534)